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The Department of Pathology & Laboratory 
Medicine is committed to providing high quality 
diagnostic services for physicians and hospitals 
nationwide. 
One of the functions of the Department is to 
update physicians throughout Pakistan about the 
advancement in laboratory sciences and the services 
available at the Clinical Laboratory for disease 
diagnosis, through our Laboratory Updates and this 
newsletter, LABRAD.  
The current issue of the LABRAD focuses on 
measurements related to bone disorders in an 
attempt to give readers a better understanding of 
the diagnostic modalities available at Aga Khan 
University Hospital Clinical Laboratories. 
Bone disease is a vast topic which interests a 
diverse group of medical professionals such 
as: internists, rheumatologist, orthopaedics, 
endocrinologist, gynaecologists, paediatricians 
and geriatrics, researchers in anatomy, physiology, 
nutrition, biochemistry, pathology and imaging. 
Diversity of interest is due to a combination 
of problems ranging from malnutrition in the 
developing world to the aging populations of the 
developed world. 
Several factors may influence the choice of a 
method for the measurement of bone disease. A 
major limiting factor in establishment of a service 
for measurement of bone diseases is the local 
availability of equipment and methodology, and 
also the availability of the required expertise and 
knowledge for the interpretation of results. Choice 
of the tests also depends on the type of information 
required from investigating a patient suspected of 
having a bone disease and achieving this aim as 
economically as possible in less time and money. 
This issue concentrates on common bone 
related clinical problems; focusing on practical 
usefulness of various tests available for diagnosis 
and management of bone diseases in the field. 
Biochemical bone profiles have been developed 
in the section of chemical pathology to help the 
physician in evaluating a patient suspected of 
having metabolic bone diseases. Combination of 
information on different microbiological tools for 
facilitating management of bone infection along 
with diagnostic tools available for identifying 
disorder like ankylosing spondylitis are also 
presented. On the whole this is a broad sweep of 
information collected through individual disciplines 
and we hope it will improve as our newsletter 
evolves through a cyclic process of learning and 
sharing with our readers.
We hope this edition would help increase your 
knowledge banks and would answer many of your 
questions. We are hopeful for making this issue a 
useful document for future reference in the bone 
disease area. Happy reading!
From the Editor’s Desk
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Commonly encountered bone diseases include those
related to vitamin D deficiency (rickets in children 
and osteomalacia in adults), osteoporosis, 
osteogenesis, imperfecta and Paget’s disease of bone. 
Bone disease  can lead to fragile and brittle bones, 
which break easily.
AKUH clinical laboratory is now providing 
Bone Health Panel, (please refer to the table 
below) which helps in assessment of bone health. 
This profile is intended to screen, investigate 
and monitor patients with disorder of calcium 
and bone metabolism. It provides answer to 
the potential clinical questions that a physician 
seeks when investigating for metabolic bone 
diseases for example; does my patient have 
hypocalcaemia or hypercalcaemia? If there is 
hypercalcaemia, is it due to hyperparathyroidism 
or a parathyroid hormone independent cause? If it 
is hypocalcaemia, is it due to parathyroid failure, 
vitamin D deficiency or renal failure? Does my 
patient have hypomagnessemia? If the patient has 
aches and pains or unexpected fracture then is it 
due to metabolic bone disease? 
Osteoporosis Panel
Osteoporosis is a systemic skeletal disorder 
characterised by low bone mass and micro 
architecture deterioration of bone tissue with 
a consequent increase in bone fragility and 
susceptibility to fracture.
The utility of bone profiles in screening and 
diagnosis of bone diseases have a profound effect 
upon bone health. Choosing any screening profile 
helps to rule  out metabolic bone diseases such as 
vitamin D deficiency, osteoporosis. Panels are made 
to make clinical interpretation easy for physicians 
and economical for patients. 
Following profiles are available at Clinical 
Laboratory AKU for diagnosis and monitoring of 
bone disorders. Only 5 ml of blood is sufficient for 
any one of the panel as shown in the Table.
Bone Health Panel
Bone health is important throughout the lifetime of 
an individual. Bones protect our internal organs from 
damage, they are the factory of our blood cells and 
are the storehouse for minerals and nutrients (such 
as calcium and phosphorus) needed in the body. 
With all of these critical functions for our health, 
understanding how to maintain and build healthy 
bones is an important part of investigating for a 
healthy future.
It is especially important to build strong and healthy  
bones during childhood and teen years to avoid 
osteoporosis and other bone problems later in life. 
After the mid-30s, bone loss slowly begins to occur.
Women lose bone quickly after menopause. 
Importantly, healthy habits can help to limit the bone 
loss that occurs. Taking care of our bones when we 
are young will help prevent problems in the future. 
Biochemical Bone Profiles Available at Clinical 
Laboratory of Aga Khan University Hospital
Dr Farhan Javed Dar
Chemical Pathology
Bone Health Panel Osteoporosis Panel
Calcium Calcium
Phosphorus Phosphorus
Albumin Albumin
Magnesium Alkaline phosphatase (ALP) 
Alkaline phosphatase (ALP) 25-hydroxy vitamin D (25-OHD) 
Creatinine  Intact parathyroid hormone (iPTH)
Intact parathyroid hormone (iPTH) N-telopeptide of type I collagen (NTx)
25-hydroxy vitamin D (25-OHD) 
Biochemical Bone Profile
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According to WHO by 2025, almost 3 million of 
the global population will suffer from osteoporosis 
which will be expected to rise to 6.3 million by 
2050. About 75 percent of this 6.3 million hip 
fractures will occur in the developing countries, 
mainly due to projected large increase of aged 
population. Osteoporosis is a costly disease due 
to its chronic nature, severity of its complications 
and means required to treat it. Osteoporosis is 
diagnosed  late as patient remains asymptomatic 
until fracture occurs. AKUH Clinical Laboratory 
is providing Osteoporosis Panel, mentioned in 
the above table, which helps in assessment of 
osteoporosis. 
It is to be noted that diagnosis should be made in 
correlation with clinical picture and Dual-energy 
X-ray absorptionetry (DXA) results. 
Plasma calcium exists in three forms ionized (iCa) 
(45 to 50 per cent), protein bound (40 per cent) and 
calcium complexed with anions (10-15 per cent). 
Although all the forms are in equilibrium with each 
other, only the plasma iCa has been reported to 
be active at cellular level. This parameter has also 
been called ‘free’ or ‘ionic’ calcium. It is considered 
the best indicator of calcium status because it 
is biologically active and tightly regulated by 
parathyroid hormone (PTH) and 1, 25 dihydroxy 
vitamin D. Total calcium level does not give an 
indication of what is available at the cellular level. 
Only disturbances in iCa are physiologically 
relevant.   
Dr Lena Jafri
Chemical Pathology
Ionized Calcium Determination in Clinical 
Labortory
Analysis of iCa is technically demanding. The sound 
analytical performance of today’s iCa analyzers 
using ion selective electrode (ISE) technology 
have made measurements accurate and precise. 
iCa recently  introduced in Aga Khan University 
Clinical Laboratory after thorough research and 
understanding of Clinical Laboratory Standard 
Institute Guidelines (CLSI) for sample handling, 
storage and transportation. Table 1 shows the 
precautions to be taken prior to blood sampling for 
iCa determination and collection.
The clinical usefulness of measuring iCa rather 
than total calcium is more in disorders with plasma 
Table 1. Recommendations for Specimen Collection of iCa as per CLSI Guidelines
Collection Techniques
If a series of tubes must be collected, fill gel tube  for iCa first
Do not leave the tourniquet on for more than 3 minutes
Do not allow the patient to exercise the forearm or make a fist
Fill gel tubes completely
Handle specimen anaerobically (do not open the tube until 
analysis)
Have the patient rest for 5-10 min before 
collecting blood 
Ensure that the patient has not eaten for at least 4 hours 
Collect specimens under consistent conditions 
ideally the patient should be seated
Precollection Variables and 
Recommendations
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Parathyroid Hormone Disorders and Issues 
of Testing
Dr Syed Talha Naeem
Chemical Pathology
Parathyroid hormone (PTH) is secreted by the 
parathyroid glands and regulates serum calcium (Ca) 
through its effects on the bone, kidney and intestine. 
PTH secretion is stimulated by decrease in serum Ca 
and magnesium and an increase in serum phosphate, 
which in turn raises serum ionized Ca levels through 
direct action on bone and the kidneys. Long-term 
regulation of total body Ca by PTH occurs through 
its stimulation of vitamin D metabolism. 
PTH can be measured in the blood in several 
different forms: intact PTH; N-terminal PTH; 
mid-molecule PTH, and C-terminal PTH. An intact 
PTH (iPTH) provides a better index of parathyroid 
function and is the test available in AKUH clinical 
laboratory for clinical use. 
PTH is secreted in episodic or pulsatile fashion 
with an overall circadian rhythm characterised by 
a nocturnal rise. Measurement of iPTH on more 
than one occasion should minimise the effect of 
episodic secretion and circadian rhythm. Because 
of the nocturnal rise in iPTH levels, samples should 
be collected in the morning, preferably after an 
overnight fast.
Determination of iPTH is useful in the differential 
diagnosis of disorders of bone and mineral 
metabolism, including hypocalcaemia and 
hypercalcaemia, renal failure and secondary 
hyperparathyroidism; when PTH increases long 
before Ca becomes abnormally low. 
PTH is elevated in the majority of patients with 
primary hyperparathyroidism. It is below normal 
or in the lower half of the reference interval in 
most patients with nonparathyroid hypercalcemia 
including hypercalcemia-associated malignancy. 
In cases with hypercalcemia, PTH estimation 
should be performed before initiating any therapy 
to reduce serum Ca; as PTH secretion may be 
stimulated by declining but still elevated levels 
of serum Ca. This can complicate the differential 
diagnosis of hypercalcaemia. In the majority of 
patients with hypercalcaemia associated with 
malignancy, iPTH is suppressed to levels below 
normal or at the lower end of the normal reference 
interval. Elevated levels of iPTH in patients with 
hypercalcemia and malignancy suggest coexisting 
hyperparathyroidism and malignancy, because 
ectopic PTH production appears to be extremely 
rare. 
In secondary hyperparathyroidism, iPTH is 
increased before total or free calcium becomes 
abnormally low, a consequence of homeostatic 
protein abnormalities like liver failure, protein losing 
nephropathy, burns, cardiac failure or malnutrition.  
iCa determination is more useful in those undergoing 
major surgery who have received citrated blood/
platelets, heparin, or intravenous calcium.
It should be the test of choice when neonatal 
hypocalcemia is suspected, especially if bicarbonate 
is given to neonates with hypocalcemia.
Rapid measurement of iCa in intensive care 
units is helpful in cases with sepsis and acid base 
disturbances. It has been documented that the use of 
total calcium is unreliable in cases where there is a 
change in the protein-calcium binding characteristics 
as in patients with hypergammaglobulinemia or a 
decrease/increase in pH. An increase in blood pH is 
associated with a decrease in iCa a decreased blood 
pH is associated with an increased iCa.
Ionized calcium is also useful in cardiopulmonary 
bypass and during hemodialysis where maintenance 
of good cardiac function is essential. During dialysis 
monitoring a slight positive calcium balance is 
important for maintaining good cardiac contractility. 
Ionized calcium is the best means to monitor this.
Literature shows that iCa rather than total 
calcium is more useful  in malignancies,  hypo/
hyperparathyroidism and pancreatitis.
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mechanisms for maintenance of serum Ca. 
Consequently, PTH is more sensitive than Ca 
for identifying secondary hyperparathyroidism. 
Subnormal or normal PTH is observed in the 
majority of patients with hypoparathyroidism; 
such concentrations are inappropriately low for 
patients with hypocalcemia.
In patients with end-stage renal disease, 
measurement of iPTH is helpful in assessing 
parathyroid function, in estimating bone turnover, 
and in improving management. Patients with 
high turnover bone disease because of secondary 
hyperparathyroidism (advanced osteitis fibrosa) have 
the highest concentrations of PTH, whereas patients 
with low-turnover, adynamic bone disease, including 
osteomalacia, have the lowest concentrations. 
Intermediate levels are found in patients with low-
turnover adynamic (aplastic) disease and early 
osteitis fibrosa. Considerable overlap in  iPTH 
levels is apparent between the various forms of renal 
osteodystrophy. 
iPTH is also useful intraoperatively, for assessing 
the completeness of parathyroidectomy and 
facilitating minimally invasive parathyroid surgery, 
thereby improving cost-effectiveness and cosmetic 
outcomes.
PTH levels may be altered in some patients with 
hyperthyroidism and hypothyroidism and may 
increase after treatment with lithium carbonate. 
PTH concentrations are inversely correlated with T3 
levels in hyperthyroid patients, increase in patients 
who become hypothyroid after radioactive iodine 
treatment, and decrease with replacement therapy; 
changes apparently mediated by serum Ca. Chronic 
lithium carbonate therapy has been reported to 
increase parathyroid gland size and circulating intact 
PTH. Drugs that may increase PTH levels include 
phosphates, anticonvulsants, steroids, isoniazid, 
lithium, and rifampicin.
Because of the physiological relationship between 
circulating Ca and PTH, it is always important to 
interpret PTH results in the light of total or ionized 
Ca levels. Indices of renal function, measurements 
of albumin, as an adjunct to measurement of total 
calcium levels and determinations of phosphorus, 
chloride, and magnesium levels may also aid in 
the interpretation of PTH and Ca results. It should 
also be remembered that hypercalcemia and 
hypocalcemia may be secondary to disordered 
vitamin D metabolism. For diagnostic purposes PTH 
results should always be used in combination with 
the clinical examination, patient medical history, and 
other findings.   
Tubular Maximum Reabsorption Rate of 
Phosphate to Glomerular Filtration Rate 
(TmP/GFR)
Phosphate filters entirely through the glomeruli 
but is then largely reabsorbed in the proximal part of 
the proximal renal tubule. Several factors influence 
the tubular reabsorption of phosphate (Table 1) by 
acting on the sodium/phosphate co transporters.
Tubular reabsorption of phosphate depends on 
plasma phosphate and glomerular filtration rate and 
is not a satisfactory indicator of tubular phosphate 
handling. This has led to increasing use of ‘tubular 
maximum for phosphate corrected for GFR (TmP/
GFR)’, a factor independent of plasma phosphate 
and renal functions for assessment of renal phosphate 
handling. TmP/GFR (Normal 2.8-4.4 mg/dL) is an 
index of renal threshold for phosphate which can 
be determined directly by the formula TmP/GFR 
= Plasma phosphate - (urine phosphate x serum 
creatinine)/urine creatinine.
Assessing renal reabsorption of phosphorus is needed 
in a variety of pathological conditions associated 
with hypophosphatemia including hypophosphatemic 
rickets, tumour-induced osteomalacia and tumoral 
calcinosis. It is also used in adjusting phosphate 
replacement therapy in severe deficiency states; 
like conditions that cause phosphate redistribution 
(e.g. glucose infusion, respiratory alkalosis), so if 
Dr Noreen Sherazi
Chemical Pathology
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hypophosphataemia persists, a low (fasting) TmP/
GFR indicates the need for phosphate replacement. 
In the treatment of severe phosphate deficiency, 
TmP/GFR can be used as an indicator of intracellular 
repletion.
 
The measurement of TmP/GFR along with other 
parameters is required for diagnosis of X-linked 
hypophosphataemic rickets and hereditary 
hypophosphataemic rickets with hypercalciuria. 
Measurement of TmP/GFR is central to the diagnosis 
of oncogenic osteomalacia in addition to other 
parameters
We, at AKUH clinical laboratory, are starting 
this test which will required at least 6-8 hours 
fasting serum sample for phosphate and creatinine 
and simultaneously taken spot urine sample for 
phosphate and creatinine. TmP/GFR will then be 
calculated from above mentioned parameters.
LABRAD Quiz
Dr Hafsa Majid
Chemical Pathology
Question #1
A three-week-old girl was brought to the emergency 
room because of intermittent twitching of her left 
limbs for 4 days. The girl had been born normally 
at 39 weeks of gestation and was being breast-fed. 
Examination was unremarkable. Her biochemical 
investigations were:
Na+ : 125mmol/l (135-145 mmol/l)  
Cl- : 100mmol/l (101-111 mmol/l)  
K+ : 2.8mmol/l (3.6-5.0 mmol/l)
HCO3 : 30mmol/l (23-28 mmol/l)
Ca+ : 4.5mg/dl (8.4-10.2mg/dl)  
Albumin : 2g/dl (3.2-5.5g/dl)
PO4 : 10mg/dl (2.5-4.6 mg/dl)
PTH : <4pg/l (16-87pg/ml) 
1.1: What is the diagnosis?
1.2: Which other bone mineral is required for   
 optimal parathyroid function?
1.3: How would this be treated?
Question #2 
A 60-year-old female came to ER due to 
fracture neck of femur after a minor fall. Her 
past complaints were of generalised body 
aches and bone pains with difficulty in rising 
from sitting position since two year.  She was 
a known case of hypertension for the past 20 
years and taking antihypertensive since then. 
She was diagnosed to be osteoporotic and was 
considered for bisphosphonate therapy. 
2.1: What is the most likely cause of body aches  
 in the patient?
2.2: What biochemical test can be performed to  
 confirm diagnosis?
2.3: How will you monitor the response to   
 bisphosphonate therapy?
Table 1. Factors Affecting Tubular Reabsorption of Phosphate
Factors that decrease renal phosphate absorption
Phosphate-free diet
Respiratory acidosis, metabolic alkalosis
PTH, PTHrP, EGF, glucocorticoids, catecholamines, calcitonin, 
1,25(OH)2 D3
Diuretics
Phosphatonins
Factors that increase renal phosphate absorption
High dietary phosphate intake
Respiratory alkalosis, metabolic acidosis
GH, IGF1, thyroid hormones (T3), insulin
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Renal Osteodystrophy:  A Disturbed Metabolic 
Aspect of Renal Failure
Renal osteodystrophy is a common complication 
of chronic kidney disease (CKD). It is part of a 
broad spectrum of disorders of mineral and bone 
metabolism that develop in this clinical setting 
and result in both skeletal and extra skeletal 
consequences. The term CKD-Mineral and 
Bone Disorder (CKD-MBD) has been recommended 
to be used to describe a broader clinical syndrome 
that develops as a systemic disorder of mineral 
and bone metabolism in CKD. The manifestations 
include abnormalities of calcium, phosphorous, 
parathyroid hormone (PTH) or vitamin D 
metabolism; abnormalities in bone turnover, 
mineralisation, volume, linear growth or strength; 
and vascular or other soft tissue calcification. 
The term renal osteodystrophy should be used 
exclusively to define alterations in the bone 
morphology associated with CKD. This is a single 
measure of the skeletal component of the systemic 
disorder of CKD-MBD that is quantifiable by 
histomorphometry of bone biopsy. The abnormalities 
of the bone in the setting of CKD may manifest 
as high turnover bone disease (ostietis fibrosa 
or secondary hyperparathyroidism), dynamic 
bone disease, osteomalacia and mixed renal 
osteodystrophy.
Biochemical markers for diagnosing renal 
osteodystrophy are intact PTH (iPTH), vitamin D 
(25OHD), blood calcium and phosphorus levels and 
bone turn over markers such as alkaline phosphatase 
and N-telopeptide of type I Collagen (NTx).  
              
The pathogenesis of osteodystrophy is complex. 
The cycle starts with the renal failure and 
retention of phosphate, inhibiting calcitriol (1,25 
dihydroxy vitamin D) synthesis and decrease 
in calcium through a reduction in intestinal 
calcium absorption. Hypocalcaemia stimulates 
PTH secretion causing high turnover renal 
osteodystrophy.  
The biochemical picture of high turnover renal 
osteodystrophy usually is an increase in blood 
PTH, bone alkaline phosphatase and phosphate 
concentration and low calcium and 25OHD levels.
Low turnover bone disease is commonly observed 
in dialysis patients, but has been described in 
some cases even before dialysis. Adynamic bone 
disease is associated with the over suppression 
of parathyroid gland activity due to high calcium 
intake (from diet, dialysate or calcium-containing 
phosphorus binders) and/or administration of 
vitamin D analogs in excess.
Patients with adynamic bone disease have lower 
blood concentrations of iPTH that may fall 
below the recommended target range of 150-300 
pg/ml of iPTH, resulting in a bone turnover rate 
that is below normal. In these circumstances, the 
bone may not take up calcium for incorporation 
into new bone and any excess calcium may 
predispose to calcification in soft tissues. 
Currently in the United States, approximately 
25 per cent of patients undergoing dialysis have 
a iPTH concentration above the target range 
(high-turnover disease), approximately 25 per 
cent have a PTH concentration within the target 
range and 50 per cent have a PTH concentration 
below the target range (adynamic bone disease).
The ultimate goal of drug therapy in 
the management of CKD is to prevent 
complications of CKD, specifically bone 
disease and extra skeletal calcification. Need 
for the evaluation, treatment and monitoring 
of bone metabolism is to prevent secondary 
hyperparathyroidism. At stage 3 CKD, serum 
calcium, phosphorus and iPTH concentrations 
should be evaluated. After initial assessment, 
routine monitoring should be performed (see 
Table 1). Appropriate management requires a 
balanced diet, phosphorus binders and active 
vitamin D analogs. The recommended ranges 
for corrected calcium, phosphorus and iPTH for 
different stages of CKD for kidney 
diseases outcomes quality initiative are shown 
in Table 2.
Dr Sahar Iqbal
Chemical Pathology
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Table 1. Monitoring of frequency of calcium, phosphorus and intact PTH in different stages of CKD kidney diseases
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
Table 2. Recommended ranges for phosphorus, corrected calcium and PTH for different stages of CKD.
National kidney foundation.  Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
Beta thalassemia major (TM) is an inherited autosomal 
recessive disorder in which synthesis of beta globin 
chains is compromised due to mutation of beta globin 
gene culminating in ineffective erythropoiesis.
The anaemia manifests at 6 to 9 months after 
birth as haemoglobin switches from HbF to HbA 
with features like failure to thrive, poor feeding, 
recurrent infections, pallor and enlarged spleen. In 
untransfused patients haemoglobin level ranges from 
3 to 6 gm/dl. However, regular blood transfusion and 
compliance with prompt iron chelation therapy has 
markedly improved life expectancy of thalassemics, 
but morbidity due to its chronic complications like 
osteopenia and osteoporosis remains there.
Osteopenia refers to bone mineral density (BMD) 
that is lower than normal peak BMD but not low 
enough to be classified as osteoporosis while 
osteoporosis is characterised by low bone mass 
and disruption of bone architecture, resulting in 
decreased bone strength with an increased risk of 
fracture.
The frequency of osteopenia or osteoporosis in 
well-treated patients of TM is approximately 40-
50 per cent which clearly depicts that despite the 
normalisation of haemoglobin levels, adequate 
hormone replacement and effective iron chelation; 
thalassemics continue to show an unbalanced bone 
turnover and an increased resorption resulting 
in seriously diminished BMD. Bone disease in 
thalassemia is manifested by diffuse bone pain, 
spinal deformities like scoliosis, nerve compression 
and various degrees of osteopenia, osteoporosis and 
spontaneous fractures. 
Factors contributing to osteoporosis and osteopenia 
in thalassemics include iron overload resulting in 
endocrinopathies; which directly or indirectly leads 
to decreased bone mass. There is marrow expansion 
due to increased erythropoiesis causing mechanical 
Osteopenia and Osteoporosis in Beta 
Thalassemia Major
Dr Huma Mansoori and Dr Shabina Sikandar
Haematology
 Stage of CKD Measurement of iPTH Measurement of Calcium and 
   Phosphorus
 3 (30-59 ml/min/1.73 m
2
 Every 12 months Every 12 months
 4 (15-29 ml/min/1.73 m
2
 Every 3 months Every 3 months
 5 (<15ml/min/1.73 m
2
 Every 3 months  Every month
Stage of CKD Phosphorus Corrected calcium  Serum PTH
 (mg/dl) (mg/dl) (pg/ml)
3 (30-59 ml/min/1.73 m
2
 2.7-4.6 Normal range 35-70
4 (15-29 ml/min/1.73 m
2
 2.7-4.6 Normal range 70-110
5 (<15ml/min/1.73 m
2
 3.5-5.5 8.9-9.5 150-300
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Role of β2 Microglobulin in Multiple Myeloma
Dr Mehreen Imran
Haematology
interruption of bone formation leading to cortical 
thinning of bones. In addition, osteoblasts are also 
affected by direct iron toxicity as well as due to liver 
disease. Chelation therapy with desferrioxamine 
inhibits DNA synthesis, osteoblast and fibroblast 
proliferation, osteoblast precursor’s differentiation 
and collagen formation, whereas in high doses it 
enhances osteoblast apoptosis.
The serum biochemistry is usually unhelpful in 
diagnosis of osteoporosis because the levels of 
calcium, phosphate and PTH are generally normal. 
However, markers of bone turnover such as serum 
alkaline phosphatase, serum osteocalcin, and N 
telopeptide of Type I Collagen (NTx) may be raised 
in osteoporosis in TM. Dual energy x-ray absorption 
(DXA scan) is also commonly used to assess bone 
mineral density but it should be kept in mind that it 
may fail to provide accurate and precise information 
on osteoporosis in thalassemics as they have spinal 
degenerative skeletal changes, which can be detected 
only by MRI and is likely to interfere with BMD 
values, resulting in false diagnosis of bone disease. 
Vitamin D deficiency can also co-exist.
Following therapeutic strategies should be 
undertaken to prevent and treat osteopenia/
osteoporosis in TM.
l lifestyle measures should be encouraged such as 
 physical activity and smoking quitting.
l calcium and vitamin D intake during skeletal 
 development increases bone mass in adult life 
 with the final goal to prevent bone loss and 
 fractures.
l induction of puberty at a proper age and 
 treatment of hypogonadism with hormone 
 replacement therapy shows quite promising 
 results to prevent osteoporosis and other bone 
 deformities. 
l calcitonin, a potent inhibitor of osteoclasts, in 
 combination with calcium and vitamin D has 
 shown to decrease bone pain and radiological 
 signs of osteoporosis.
l alendronate, pamidronate, and zoledronic 
 acid have shown efficacy in osteoporotic patients 
 with TM either with normal or impaired gonadal 
 function but further research in the therapeutic 
 trials with bisphosphonates is needed to allow 
 definite conclusions especially in our setting 
 where vitamin D deficiency is widely prevalent. 
 However, they may be used as a second line 
 treatment if the above strategies have failed.
Multiple myeloma is a B cell malignancy 
characterised by monoclonal accumulation of 
abnormal plasma cells in the bone marrow (Fig. 
1). The clinical signs and symptoms of myeloma 
are heterogeneous and include bone complications, 
symptoms of impaired formation of blood cells 
and hyperviscosity, renal dysfunction, infections, 
peripheral neuropathy and extra medullary disease.
Multiple myeloma constitutes about 15 per cent of 
the haematological malignancy. The disease develops 
in one to four per 100,000 people per year. It is 
more common in men, and is twice as common in 
blacks as it is in whites. With conventional treatment, 
the prognosis is three to four years, which may 
be extended to five to seven years or longer with 
advanced treatments.
Diagnostic work up for myeloma is shown in 
Table 1. One of the laboratory parameter is β2 
microglobulinFig. 1. Bone marrow aspirate demonstrating plasma cells of multiple myeloma
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microglobulin level in the blood to increase. Pre-
treatment values of β2 microglobulin are thus useful 
in confirming tumor mass grade, and in assessing 
response to chemotherapy; marked reductions 
following chemotherapy correlated well with the 
onset of remission. The serum β2 microglobulin 
level is one of the prognostic factors incorporated 
into the International staging system. Patients with 
high values have inferior survival.
The following levels of β2 microglobulin correlate 
with stages of multiple myeloma:
Stage I multiple myeloma
l β2 microglobulin level is lower than 3.5 mg/mL
l albumin level is 3.5 g/dL or higher
Stage II multiple myeloma
l β2 microglobulin level is lower than 3.5 mg/mL  
 and the albumin level is lower than
 3.5 g/dl
l β2 microglobulin level is between 3.5 and 5.5  
 mg/mL
Stage III multiple myeloma
l β2 microglobulin is 5.5 mg/mL or higher. 
 
The prognostic value of serum β2 microglobulin 
level in myeloma is probably due to correlation 
of levels with tumour burden. High levels are also 
associated with renal failure, which carries an 
unfavourable prognosis in multiple myeloma. The 
reference ranges are shown in Table 2.
β2 microglobulin test is performed by a 
chemilumniscent assay in Clinical Laboratory 
AKUH. It is done on clotted blood sample of the 
patient; however, it can also be performed on 
patient’s urine. Urine may be a single collection 
or collected throughout a 24 hour time period. The 
urine should be refrigerated until it is brought to the 
laboratory and must not become acidic. 
Table 2. Reference Ranges for β2 Microglobulin as Reported in 
AKU-Laboratory
Males 1,556 604 2,157 2,284  424
Females 1,473 607 2,295 2,454 370
Magnetic resonance imaging (MRI)
(also known as β2M) is a component of MHC class 
I molecules, which are present on all white blood 
cells (including plasma cells). In humans, the β2 
microglobulin protein 
is encoded by the β2 
microglobulin gene 
(Fig. 2). Normal 
urinary excretion 
of β2 microglobulin 
is less than 370 
micrograms per 
24 hours. Elevated 
serum concentration 
in the presence of 
normal glomerular 
filtration rate 
suggests increased 
β2 microglobulin 
production or release, 
which is seen in 
lymphoproliferative 
diseases such as 
multiple myeloma. 
The increase is seen in cancers involving white 
blood cells, but it is more meaningful in newly 
diagnosed multiple myeloma patients. Increased 
production or destruction of plasma cells causes β2 
Table 1. Laboratory and Radiological Work ups for Multiple 
Myeloma Available at AKUH
Fig. 2. Structure of MHC class I β2     
microglobulin
Laboratory Tests
Full blood count, peripheral film and ESR
Evaluation of kidney function, serum calcium, CRP, β2 
microglobulin, LDH, uric acid levels and liver function tests
Protein electrophoresis and paraprotein quantification
Quantitative analysis of normal immunoglobulins,
24-hours urine collection for light chain (Bence Jones protein) 
excretion, coagulation screen
Bone marrow aspiration and trephine biopsy for morphology, 
immunophenotyping (CD138, CD79a, kappa, lambda, CD20) 
and cytogenetic
Radiological Tests
Complete skeletal survey
Computerised tomography (CT)
   ng/mL
Group Median 2.5%ile 95%ile 97.5%ile N
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on (for example, coagulase negative staphylococci, 
Propionibacterium acnes) (Table 1). 
Laboratory Investigations
Detection of inflammatory markers:
Baseline blood tests for inflammatory markers 
including C reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), leukocyte count should be 
performed for any suspected case. These parameters 
may be elevated up to two weeks after surgery 
and cannot be relied upon in early infection. Serial 
measurements of these markers are recommended 
and persistently or progressively high inflammatory 
markers most likely reflect infection. It is important 
to note however, that a normal result does not exclude 
joint infection especially if the pathogen is of low 
virulence. 
Cultures:
Blood for culture should be taken in every case 
before starting antibiotics as even a single dose is 
known to decrease the diagnostic yield. In most cases 
however, it is difficult to take deep cultures before 
starting antibiotics in patients with systemic sepsis or 
rapidly evolving local infection. 
Superficial swabs should not 
be collected as they most likely 
reflect colonising flora and 
results must
therefore be interpreted with 
caution. Deep samples of 
synovial fluid and tissue taken 
during arthrotomy/arthroscopy, or 
by joint aspiration are needed for 
definitive diagnosis. Organisms 
should be identified accurately 
as treatment options differ for 
different organisms (Fig.1 and Fig. 
Prosthetic joint infections (PI) are associated with 
substantial morbidity and costs; therefore early 
and accurate diagnosis is crucial. The clinical 
presentation may be non-specific and vary between 
different patient populations. Effective use of the 
currently available diagnostic modalities for PI 
results in improves outcomes. PI occurring within 
three months of joint replacement are categorized as 
early and 3-12 months after surgery as delayed and 
>12 months as late.
A widely accepted case definition for PI includes: 
l purulence around a prosthesis at arthrotomy or  
 arthroscopy
l presence of one or more sinus tract    
 communicating with the joint
l histological features of infection
l isolation of similar organism from at least two  
 deep culture samples. Isolation of virulent   
 organisms, such as Staphylococcus aureus,   
 Escherichia coli, or Candida spp., in one deep 
 tissue sample may be considered as significant 
 to confirm the diagnosis. 
Gram positive organisms, especially Staphylococci 
(commensal skin organisms), are most commonly 
involved and in early infection, pathogens are usually 
more virulent (for example, Staphylococcus aureus),
whereas more indolent organisms predominate later 
Update on Microbiological Diagnosis of Bone 
and Joint Disorders
Dr Kauser Jabeen, Dr Salima Qamar
Microbiology
Prosthetic Joint Infections; How to Effectively use the Available 
Diagnostic Modalities?
Types: PJI can either be acute, chronic or secondary to hematogenous seeding.
Etiologies of Prosthetic Joint Infection
Etiology
S. aureus
B-hemolytic Strep
Gram-negatives 
Coagulase-negative Staph
Corynebacteria
Gram-negatives
Inciting event from prior 
infection in other area of the body
Type of Infection
Early Postoperative 
Infection (<3 weeks)
Chronic Infection
(>3weeks)
Hematogenous seeding
Time of Onset
Symptoms within days to 
weeks of surgery
Symptoms several months 
to 2 years after prosthesis 
placement
Within days of inciting event
14
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Other diagnostic modalities:
Apart from culture histopathology is an essential 
adjunct to microbiology in the diagnosis of infection. 
An elevated white cell count and neutrophil differential 
of the synovial fluid are also suggestive of infection. 
Serial plain radiographs may help in detecting 
loosening or bone loss in chronic PI. Ultrasound should 
be performed to confirm effusion and to facilitate 
aseptic aspiration. Computed tomography and magnetic 
resonance imaging may be useful in the evaluation of 
complex cases, but metal inserts interfere with these 
tests, and abnormalities may be non-specific.
2). Identification of similar organisms from at least 
three culture samples is highly predictive of infection 
and to increase sensitivity and specificity multiple 
(five to six) samples should be sent for culture (Box 1). 
Organisms associated with prosthetic-joint infection 
usually form biofilms thus culture of prosthesis by 
vortexing and sonication than conventional peri-
prosthetic tissue culture is more sensitive and specific 
especially in patients with prior antibiotic treatment. 
Cultures should also be held for longer duration if fungi 
or mycobacteria are suspected as causative organisms.
Fig. 1. Coagulase test that is required to differentiate between Staphylococcus 
aureus and other Staphylococcus species; two most common organisms respon-
sible for prosthetic joint infections. Upper tube is coagulase positive confirming 
the identity of this organisms as Staphylococcus aureus
Fig. 2. Photomicrograph on the left showing Gram stain of Propionibac-
terium species; this organisms requires anaerobic conditions
Bone and Joint Infections: Laboratory Diagnosis
Bone and joint infections occur as a result of 
haematogenous seeding, contiguous spread of 
infection to bone from adjacent soft tissues, or direct 
inoculation of infection as a result of trauma or surgery. 
Haematogenous spread is more common in children 
while contiguous spread is commoner in adults. 
Contiguous infection may be either polymicrobial 
or monomicrobial while haematogenous infection 
is usually monomicrobial. Staphylococcus aureus, 
coagulase-negative staphylococci, and aerobic gram-
negative bacilli are the most common organisms; less 
common pathogens include streptococci, enterococci, 
fastidious gram negative organisms and anaerobes. 
Mycobacteria, Brucella spp. and fungi have also been 
reported in appropriate endemic and clinical settings.
Diagnosis; General Considerations
Cultures: Several factors should be considered while 
investigating for the diagnosis of these infections. 
The most important factor is specimen collection as 
it is extremely important to prevent contamination 
by normal flora. The samples should be collected as 
tissue or fluid rather than swabs because:
l they are more likely than tissue or fluid to be  
 contaminated
l the amount sent for culture is often insufficient
l they may inhibit the growth of certain pathogens
l fastidious organisms survive less well in   
 swabs than in aspirated fluid or pus
l bacteria may adhere to swabs and give a   
 false-negative microscopy result
Ideally, culture specimens should be taken before 
antibiotics are commenced. In practice, however, 
empirical antibiotics may be commenced before 
culture specimens are taken.
Box 1. Recommendations to improve yield of cultures for diagnosis of PJIs
	 l Intraoperative histopathological examination of periprosthetic tissue obtained during surgery
	 l At least 3 and optimally 5 or 6 periprosthetic intraoperative tissue samples or the explanted prosthesis
	 l Withholding antimicrobial therapy for at least 2 weeks prior to collection of samples
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Bone and Joint Infections: Laboratory Diagnosis
If Mycobacteria or fungi are suspected as 
etiologic agents; specimens should be sent for 
mycobacterial and fungal culture in addition to 
culture for routine organisms. 
Histopathology: Histopathology and cytology not 
only provide rapid results than culture but also 
guide in assessing the significance of cultures. 
However the tissue Gram stain is an insensitive 
test for detecting bacteria as fixing and processing 
including chemical decalcification, adversely 
affects the Gram stain characteristics. 
Nucleic acid amplification tests: There is little 
published information regarding the role of nucleic 
acid amplification based methods for skin, bone, joint, 
and soft-tissue infections. Therefore, routine use of 
nucleic acid amplification is not recommended for the 
diagnosis of these infections. Although these techniques 
may prove useful in selected cases where fastidious 
organisms are suspected as cause of infection. 
Bone Infections
Close communication between clinician, radiologist 
and pathologist/microbiologist is required for optimum 
diagnosis. Excisional bone biopsy is required in cases 
in which clinical and radiographic features are not 
diagnostic. In all cases however, culture is essential for 
identification and antimicrobial susceptibility testing. 
For that an adequate amount of tissue should be sent to 
the microbiology laboratory. For chronic osteomyelitis, 
culture of an infected bone specimen is necessary 
to establish the diagnosis. Blood culture should also 
be sent to aid the diagnosis if the patient is septic. A 
positive culture precludes the need for more invasive 
procedures if the organism isolated from blood is a 
likely pathogen to cause osteomyelitis.
Cultures of superficial wounds and sinus tracts are 
of no value because the results do not correlate 
reliably with the pathogen in the underlying bone 
except if Staphylococcus aureus or Salmonella spp 
are isolated (Fig. 1). 
Serial measurements of serum C-reactive protein 
levels and erythrocyte sedimentation rates are also 
commonly used to monitor response to therapy. The 
CRP is a more sensitive parameter than the ESR.
Joint Infections
Synovial fluid analysis is useful in establishing 
diagnosis and presence of pus suggest  the 
possibility of infection (Fig. 2). Joint fluid 
should be cultured for both aerobic and anaerobic 
bacteria. Blood culture bottles should not be 
used to culture joint fluid as they have not been 
evaluated for yield for culturing joint fluid (Fig. 
3). Fluid aspirated from joints should be collected 
aseptically, transferred to a sterile container (or 
left in the syringe), and sent immediately to the 
laboratory. Cultures for Neisseria gonorrhoeae 
should be transported immediately to the 
laboratory. Specimens to be submitted for 
mycobacterial culture do not require special 
handling. Fig. 1. Swabs from superficial wounds and sinus tract should not be sent as the organisms isolated do not correlate with the pathogen in bone
Fig. 3. Blood culture bottles should not be used to culture joint fluid; 
fluid aspirated should be transferred to a sterile container
Fig. 2. Pus sample aspirated from infected knee joint highly suggestive of 
infection. Photomicrograph on the right is showing Gram stain of same 
sample revealing numerous pus cells and Gram positive cocci in clusters
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Mycetoma is a chronic inflammation of skin 
and subcutaneous tissue caused by either 
fungi (eumycetoma) or filamentous bacteria 
(actinomycetoma). This infection most commonly 
presents as a progressive, subcutaneous swelling with 
development of multiple nodules. These nodules later 
develop into sinuses with discharging grains (Fig. 1). 
As the disease progresses involvement of bones 
and in advanced cases osteoporosis and bone 
destruction can occur. The organisms responsible 
for mycetoma are present in the soil and enter 
the subcutaneous tissue by traumatic inoculation. 
This infection is mainly seen in tropical regions 
and Pakistan is one of the endemic countries. 
Mycetoma commonly affects adults aged 20 to 40 
years, predominantly males. The foot is the most 
commonly affected site  (80 per cent of the cases). 
Diagnosis
Diagnosis is usually determined clinically; however 
radiology is required to assess the extent of 
spread and involvement of bone and joints. Visual 
examination of colour of discharging grains is 
crucial for identification of possible etiologic agent 
(Fig. 2). In addition to that microscopic examination 
after crushing the grains between two slides should 
be performed to visualise fungal or bacterial 
elements (Table 1). Specimen should also be cultured 
for fungi and aerobic actinomycetes (Fig. 3). If 
granules are not present, an excisional biopsy for 
culture and histopathology or cytology is essential. 
Histopathology is also important for correlation with 
Fig. 1. Mycetoma of the foot                          
Mycetoma: Microbiological Diagnosis
cultures as the specimens may become contaminated 
with bacteria or fungi from skin or sinus tracts. The 
superficial material from sinus tracts should never be 
sent for culture as it will likely grow mixed flora that 
does not represent the actual cause of infection.
Fig. 2. Discharging grain from a case of mycetoma
Fig. 3. Culture plate and photomicrograph showing Madurella spp.; 
commonest agent of eumycetoma
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Table 1. Common Etiologic Agents of Mycetoma
Etiologic Agents Colour of the Grains
Eumycetoma Species
Madurella mycetomatis Black
Madurella grisea Black
Fusarium spp White
Acremonium spp White
Actinomycetoma Species
Nocardia brasiliensis White
Nocardia asteroides White
Streptomyces somaliensis White
Actinomadura madurae White
Actinomadura pelletieri Red
Diabetic foot infection (DFI) is a frequent clinical 
problem. DFIs typically begin in a wound, most often 
a neuropathic ulceration or traumatic wound. 
The presence of infection is defined by the presence 
of more than two signs of inflammation or purulence 
or secondary signs (Table 1). Most DFIs are 
polymicrobial with Staphylococcus aureus and beta 
hemolytic streptococci the most common causes 
of infection (Table 1). Gram-negative bacilli are 
commonly seen in chronic wounds or in those 
patients who have received prolonged prior antibiotic 
treatment. Anaerobes may be co-pathogens in 
ischemic or necrotic wounds.
l Severity
Infections are classified into mild (superficial), 
moderate (deeper or more extensive), or severe 
(accompanied by systemic signs). This classification 
system helps to direct the management of patient, 
requirement of imaging procedures, surgical 
interventions or amputation. Accurate and timely 
diagnosis and proper management is crucial to avoid 
unnecessary amputations, morbidity and mortality. 
l Sample collection
Microbiological cultures play an inevitable role in 
management of DFIs. Whenever there is suspicion 
of infection, appropriately obtained specimens for 
culture prior to starting empiric antibiotic therapy 
should be sent as therapy may be for a prolonged 
duration. Specimen from deep tissue is obtained 
by curettage or scraping of tissue from the ulcer 
base using a dermal curette or sterile scalpel blade 
after the wound is properly cleansed and debrided. 
Aspirate and purulent secretions collected using a 
sterile needle can also be used. Swab specimens 
should be avoided as results are less accurate. 
Collected specimens should be 
immediately sent in a sterile container and 
appropriate transport media to microbiology lab.
l Management and follow-up
Clinically uninfected wounds do not require 
antibiotic therapy. Empiric antibiotic therapy should 
only be commenced when there is suspicion of 
infection: it should target the likely etiologic agent. 
A combined surgical and medical approach, with 
Microbiological Diagnosis of Diabetic Foot 
Infections
Dr Tazeen Fatima
Microbiology
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either oral or parenteral antibiotics, is recommended 
according to severity of the lesion. Per oral coverage 
for aerobic gram-positive cocci (GPC) is sufficient 
for one - two weeks for mild to moderate infections 
in patients without recent antibiotic exposure. For 
more severe infections, two – three weeks of broad-
spectrum parenteral empiric antibiotic therapy with 
gram positive, 
anti-pseudomonal 
and anaerobic 
coverage is 
recommended. 
Definitive therapy 
should be based 
on the results of 
an appropriately 
obtained culture 
and sensitivity 
testing of a wound 
specimen as well 
as the patient’s 
clinical response 
to the empiric 
regimen. Bony 
abnormalities 
(deformity, 
destruction, soft 
tissue gas) should 
be ruled out by 
plain radiographs 
or MRI scans of 
the affected foot. The therapy should be at least 4 
weeks when there is accompanying osteomyelitis 
unless all infected tissue has been resected. A close 
follow-up of wound and limb condition is necessary 
to identify when re-culturing and re-debridement is 
required.
along with their novel genetic changes. The 
advances in classifying and understanding the 
pathogenesis of bone Tumours based on the 
correlation of histologic and genetic findings 
have been particularly significant in the field of 
bone oncopathology, perhaps more so than in 
many other areas of pathology, with the exception 
of hematolymphoid neoplasia. Although many 
interesting molecular genetic findings have 
been described in bone tumours, this article will 
focus on changes in the classification of bone 
Introduction
The 4th edition of World Health Organization 
(WHO) Classification of Tumours of Soft Tissue 
and Bone was published in 2013 almost 11 years 
after the prior volume of 2002. Many changes 
have taken place in bone tumor classification 
during this period predominantly based on the 
identification of new genetic findings in different 
tumor types. Also, several new morphologically 
distinct tumor types have been described, often 
Classification of Tumours of Bone: an Update 
Based on the 2013 World Health Organization 
Classification of Tumors of Soft Tissue and Bone
Dr Nasir Ud Din
Histopathology 
Table 1. Diagnosis of Diabetic Foot Infections
Clinical Signs of Infected Diabetic Foot
Inflammatory signs (>2)
Purulent secretions
Secondary signs
Other signs
Systemic signs of infection
Etiology (Mostly Polymicrobial)
Gram positive
Gram negative
Anaerobes
Fungal (rare)
Redness, warmth, swelling, tenderness, or pain
Non-purulent secretions, discolored granulation tissue, 
undermining of wound edges, foul odor
Positive probe-to-bone (PTB) test, ulceration for >30 days, 
recurrence, peripheral vascular disease or a previous lower limb 
amputation and loss of protective sensation
Fever, tachycardia, hypotension, and metabolic abnormalities 
(acidosis, dysglycemia, electrolyte abnormalities, worsening 
azotemia), and deranged laboratory markers (leukocytosis, 
elevated ESR, CRP or procalcitonin)
Staphylococcus aureus (most common), beta-hemolytic strep-
tococci (groups A, F, B, C, G), enterococci, coagulase negative 
staphylococcus (especially with osteomyelitis), corynebacteria
Pseudomonas aeruginosa, Enterobacteriaceae (E.coli, Klebsiella 
and Enterobacter species, Proteae), Aeromonas species etc.
Peptostreptococcus species, Bacteroides species (fragilis group), 
Prevotella species and Clostridia
Mucoraceous (Rhizopus, Mucor, Absidia species etc.), Fusarium 
species
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clinical implications. The changes are reviewed 
according to the categorization of Tumours in the 
WHO volume. These changes, along with those in 
bone Tumours, are summarized in Table 1.
sarcomas as well as bone tumours of intermediate 
biologic potential (ie, locally aggressive or rarely 
metastasizing tumours), new molecular insights 
into these tumours, and associated surgical and 
 Table 1. WHO Classification of Tumours of Bone
CHONDROGENIC TUMOURS
Benign
Osteochondroma
Chondroma
   Enchondroma
   Periosteal chondroma
Osteochondromyxoma
Subungual exostosis
Bizzare parosteal osteochondromatous proliferation
Synovial chondromatosis
Intermediate (locally aggressive)
Chondromyxoid fibroma
Atypical cartilage tumour/Chondrosarcoma grade I
Intermediate (rarely metastasizing)
Chondroblastoma
Malignant
Chondrosarcoma
     Grade II, grade III
Dedifferentiated chondrosarcoma
Mesenchymal chondrosarcoma
Clear cell chondrosarcoma
OSTEOGENIC TUMOURS
Benign
Osteoma
Osteoid osteoma
Intermediate (locally aggressive)
Osteoblastoma
Malignant
Low –grade central osteosarcoma
Conventional osteosarcoma
      Chondroblastic osteosarcoma
      Fibroblastic osteosarcoma
      Osteoblastic osteosarcoma
Telangiectatic osteosarcoma
Small cell osteosarcoma
Secondary osteosarcoma
Parosteal osteosarcoma
Periosteal osteosarcoma
High grade surface osteosarcoma
FIBROGENIC TUMOURS
Intermediate (locally aggressive)
Desmoplastic fibroma of bone
Malignant
Fibrosarcoma of bone
FIBROHISTIOCYTIC TUMOURS
Benign fibrous histiocytoma/Non-ossifying 
fibroma
HAEMATOPOIETIC NEOPLASMS
Malignant
Plasma cell myeloma
Solitary plasmacytoma of bone
Primary non-Hodgkin lymphoma of bone
OSTEOCLASTIC GIANT CELL RICH TUMOURS
Benign
Giant cell lesion of the small bones
Intermediate (locally aggressive, rarely metastasizing)
Giant cell tumour of bone
Malignant
Malignancy in giant cell tumor of bone
NOTOCHORDAL TUMOURS
Benign
Benign notochordal tumour
Malignant
Chordoma
VASCULAR TUMOURS
Benign
Haemangioma
Intermediate (locally aggressive, rarely metastasizing)
Epithelioid hemangioma
Malignant 
Epithelioid hemangioendothelioma
Angiosarcoma
MYOGENIC TUMOURS
Benign 
Leiomyoma of bone
Malignant
Leiomyosarcoma of bone
LIPOGENIC TUMOURS
Benign 
Lipoma of bone
Malignant
Liposarcoma of bone
TUMOURS OF UNDEFINED NEOPLASTIC NATURE
Benign
Simple bone cyst
Fibrous dysplasia
Osteofibrous dysplasia
Chondromesenchymal hamartoma
Rosai-Dorfman disease
Intermediate (locally aggressive)
Aneurysmal bone cyst
Langerhans cell histiocytosis
Erdheim-Chester disease
MISCELLANEOUS TUMOURS
Ewing sarcoma
Adamantinoma
Undifferentiated high grade pleomorphic sarcoma of bone
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Fibrogenic Tumours
The definition of “fibrosarcoma of bone” is 
clarified as an intermediate- to high-grade spindle 
cell malignant neoplasm that lacks significant 
pleomorphism and lacks any line of differentiation 
other than fibroblastic. This clarification addresses 
several issues. First, a fascicular or “herringbone” 
pattern of growth may be observed in many different 
tumor types that can be classified in other specific 
diagnostic categories. Second, this pattern of growth 
may also be seen in otherwise unclassified high-
grade pleomorphic sarcomas, and if significant 
pleomorphism is present the tumor is best classified 
as the latter. Fibrosarcoma of bone is therefore a 
diagnosis of exclusion, and the diagnosis cannot 
be made on limited biopsy samples, because 
thorough sampling is needed to exclude other lines 
of differentiation. The incidence of fibrosarcoma is 
likely much less than the five percent documented in 
the prior WHO classification.
Fibrohistiocytic Tumours
Similar to soft tissue tumor classification, the category 
of “malignant fibrous histiocytoma” of bone has been 
removed from the 2013 classification of bone Tumours.
Ewing Sarcoma
The term PNET has been removed as a synonym 
for Ewing sarcoma. Of round cell sarcomas of 
bone that do not fulfill criteria for Ewing sarcoma, 
two genetically distinct groups of Tumours have 
been recognized that harbor CIC-DUX4 or BCOR-
CCNB3 fusion genes.
Osteoclastic Giant Cell-Rich Tumours
In this category, “giant cell tumor of bone” is now 
separated from “giant cell lesion of the small bones.” 
Giant cell lesion of the small bones is a very rare 
tumor-like lesion that arises in the small bones 
of the hands and feet and commonly recurs after 
initial curettage, but is almost always cured after the 
second excision. Giant cell tumor of bone is a locally 
aggressive neoplasm that may very rarely metastasize 
or undergo malignant transformation into a high-
grade sarcoma, either de novo or after radiotherapy.
Notochordal Tumours
Benign notochordal cell tumor was added to this 
category, which previously only included chordoma. 
Chondrogenic Tumours
Osteochondromyxoma is a new addition to this 
category, which is a benign but locally aggressive 
tumour exhibiting both osteoid and chondroid 
production. This rare tumor arises in approximately 
one percent of patients with Carney complex. Sites 
of involvement include the tibia and sinonasal bones, 
and destructive growth with extension into soft tissue 
can occur. Disease recurrence is more likely at sites 
where complete resection is difficult; metastases have 
not been reported. 
Chondrosarcoma is now separated into two groups, 
with grade one distinguished from cases of grade 
two and grade three chondrosarcoma. In addition, 
the synonym “atypical cartilaginous tumor” was 
introduced for “grade one chondrosarcoma.” These 
Tumours are locally aggressive but metastasize 
only extremely rarely; the five year survival rate 
is 83 percent, with death from disease occurring 
due to uncontrollable tumor growth, especially in 
patients with pelvic Tumours. Curettage/simple 
excision alone is considered adequate treatment. For 
those Tumours that recur, approximately 10 percent 
demonstrate an increase in cellularity warranting 
a change in grade. In contrast, grade two and three 
chondrosarcomas frequently metastasize and have 
a five year survival rate of 53 percent; en bloc 
resection is recommended for this group of patients. 
Tumours should be graded based on the area of 
highest histologic grade in cases in which variable 
histologic grades exist within the same tumor.
Osteogenic Tumours
The only change in the classification of osteogenic 
Tumours is the incorporation of secondary 
osteosarcoma into the category of conventional 
osteosarcoma for descriptive purposes. Conventional 
osteosarcoma is subclassified based on histologic 
features (e.g, osteoblastic, chondroblastic), but 
there remains no relationship between the subtype 
of conventional osteosarcoma and treatment and 
prognosis, in contrast to other types of osteosarcoma.
Amplification of mouse double minute two homolog 
(MDM2) and cyclin-dependent kinase 4 (CDK4) 
have now been well documented in low-grade 
central osteosarcoma and parosteal osteosarcoma, 
and immunohistochemistry for these two markers 
can be a helpful tool, especially in those cases that 
have undergone dedifferentiation to a high-grade 
osteosarcoma and in which recognition of the precursor 
low-grade lesion is difficult clinically or pathologically.
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This benign tumor may represent persistent 
notochord rather than a true neoplastic proliferation; 
benign notochordal cell tumor arises at the base of 
skull, vertebral bodies, and sacrococcygeal bones and 
is usually an incidental finding.
Vascular Tumours
Hemangioma has been separated from epithelioid 
hemangioma, a recently characterized neoplasm 
composed of small vessels lined by epithelioid 
endothelial cells. Epithelioid hemangioma most 
often arises in long tubular bones, followed by flat 
bones and vertebrae. In contrast to conventional 
hemangioma, epithelioid hemangioma is locally 
aggressive: recurrence occurs in approximately 10 
percent of cases. Treatment consists primarily of 
curettage, and less often local resection. Epithelioid 
hemangioma should also be distinguished from 
epithelioid hemangioendothelioma (EHE), which is 
classified as a malignant neoplasm that demonstrates 
endothelial differentiation, and the mainstay of 
treatment is wide resection. The mortality rate is 
approximately 20 percent and histologic features 
do not predict the development of metastases.  
Recurrent fusion genes have been identified in EHE, 
namely WWTR1-CAMTA1 and YAP1-TFE3. These 
fusion genes are not present in angiosarcoma or 
benign vascular Tumours. 
Undifferentiated High-Grade Pleomorphic Sarcoma
High-grade pleomorphic malignant Tumours that 
lack a specific line of differentiation are classified 
as “undifferentiated high-grade pleomorphic 
sarcoma.” This diagnosis is one of exclusion, and 
thorough sampling is needed to exclude osteoid 
deposition, which would necessitate a diagnosis of 
osteosarcoma, as well as other histologic features 
that may suggest a specific diagnosis.Tumours in this 
category have a metastatic rate of at least 50 percent. 
Treatment generally involves neoadjuvant therapy 
followed by wide excision for potentially resectable 
lesions. Similar to osteosarcoma, the degree of 
tumor necrosis after neoadjuvant chemotherapy is an 
important prognostic factor.
Conclusions
Since the publication of the prior WHO 
Classification of Tumours of Soft Tissue and Bone 11 
years ago, new clinicopathologic and genetic features 
of many bone Tumours have been characterized, 
which has led to more reproducible classifications 
of these Tumours and therefore more effective 
treatment stratification. This has also allowed 
obsolete tumor types such as the so called malignant 
fibrous histiocytoma to be removed from the 2013 
WHO classification. In addition, several new entities 
have been included for the first time in this volume.
Recent Developments in Benign Bone Tumours
Dr Nasir Ud Din
Histopathology
Introduction
Benign tumours of bone frequently pose a diagnostic 
challenge for general surgical pathologists.
Careful clinical and radiological correlation is required 
for accurate diagnosis. Significant recent advances 
in some benign bone tumours have occurred at the 
molecular and cytogenetic level, which have provided 
a better understanding of the pathophysiology of 
certain tumours. It has also provided an important aid 
in the diagnostic workup and differential diagnosis of 
some bone lesions demonstrating overlapping clinical 
and pathologic features. Prognostic and therapeutic 
applications of these findings are the future directions. 
For the treatment of certain benign bone tumours, 
newer less invasive therapeutic techniques and 
medical management have been developed.
Osteoid Osteoma
Osteoid osteoma is a benign bone-forming tumour 
commonly arises in the cortex of diaphysis or 
metaphysis of long bones (femur and tibia) or 
posterior vertebral elements in second and third 
decades of life. The typical presentation is nocturnal 
pain relieved by nonsteroidal anti-inflammatory drugs 
(NSAIDs). The pain is caused by local production of 
high levels of prostaglandin E2, which is mediated by 
cyclooxygenases (COX-1 and COX-2).
Radiographically, osteoid osteoma classically
presents as an area of cortical thickening and 
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sclerosis containing a lucent focus “nidus” of less 
than two cm. Histologically, the nidus consists of 
an interlacing network of woven bone trabeculae 
with variable mineralization in a loose fibrovascular 
stroma (Figure 1). The bone trabeculae are rimmed 
by osteoblasts, with scattered osteoclastic-type 
multinucleated giant cells.
Recent development in osteoid osteoma is in its 
treatment, to control pain. Minimally invasive 
techniques have been developed include CT-
guided core drill excision, percutaneous 
radiofrequency ablation (RFA), cryoablation, or 
laser photocoagulation. Radiofrequency ablation has 
gained great popularity because of its advantages 
over traditional surgery. It is minimally invasive, 
safe, and highly effective (pain relief within 24 hour to 
one week after treatment). It is useful in the treatment 
of lesions in atypical or technically challenging 
locations (intra-articular, spinal, or short bone lesions). 
Tissue necrosis is induced by thermal coagulation 
through insertion of an electrode into the lesion. The 
main advantages of the procedure include minimal 
bone loss and structural weakening, less morbidity 
(infections), shorter anesthesia, minimal restriction of 
physical activity, short hospitalization and recovery 
time (usually a few hours), and lower cost.
Osteoblastoma
Osteoblastoma is a rare, benign bone neoplasm 
which is histologically and clinically similar to 
osteoid osteoma but has a potential for progressive 
growth and local recurrence. It is characterized 
by larger size (>2 cm) and dull pain that may not 
be relieved by NSAIDs. The peak incidence is in 
the second decade of life and it is more common 
in males. Osteoblastoma has predilection for the 
axial skeleton (posterior vertebral elements) but 
also occurs in the appendicular long bones and the 
mandible. Most cases are radiographically round to 
oval, well-demarcated, lytic lesions surrounded by a 
rim of reactive bone. Histologically, osteoblastoma 
is similar or identical to the nidus of an osteoid 
osteoma. It is composed of inter anastomosing 
trabeculae of woven bone in a loose fibrovascular 
stroma with conspicuous osteoblastic rimming and 
abundant osteoclasts (Figure 2). The lesion is sharply 
demarcated from the adjacent bone and is often 
surrounded by a rim of reactive bone. Osteoblastoma 
does not permeate cortical and host bone or invade 
into soft tissue. 
A unique three-way translocation involving 
chromosomes 1, 2, and 14 [t(1;2;14)(q42;q13;q24)] 
and rearrangement of 1q42 have been reported in 
osteoblastoma. 
An epithelioid variant of osteoblastoma has been 
described with a tendency to local recurrence but no 
metastatic potential has been described. Conventional 
osteoblastoma has a good prognosis with a local 
recurrence rate of 16 percent – 20 percent. The 
tumors are treated with surgical removal either by 
curettage or by en bloc resection. 
Fibrous Dysplasia
Fibrous dysplasia (FD) is a dysplastic anomaly of 
bone forming mesenchymal tissue. There is focal or 
multifocal inability to produce lamellar bone, with 
an arrest at the level of woven bone. This leads to 
the formation of a mass of immature isolated woven 
bone trabeculae enmeshed in dysplastic fibrous 
tissue which never complete the remodeling process. 
Consequently, there is substantial loss of mechanical 
strength, pain, deformity, and pathologic fractures.
Most lesions are diagnosed before the age of 30 
years. It may be monostotic or polyostotic. The 
monostotic form represents 60 percent or more 
of all patients with the disease and it is usually 
asymptomatic. Fibrous dysplasia may develop in 
Figure 1. Osteoid osteoma exhibiting interconnecting  bone trabeculae with 
osteoblastic rimming and loose fibrovascular stroma 
Figure 2. Osteoblastoma showing interconnecting  bone trabeculae with 
osteoblastic rimming and loose fibrovascular stroma and few osteoclasts
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practically any bone (craniofacial bones, femur, 
tibia, and ribs are preferred sites). Radiologically the 
lesions are lytic and expansile, with thinning of the 
adjacent cortices and internal “ground glass” pattern 
of opacification caused by mineralization of the 
woven bone trabeculae. 
Histologically, FD is composed of cytologically 
bland spindle cells with interspersed slender 
trabeculae of woven bone devoid of prominent 
rimming osteoblasts or osteoclasts (Figure 3). 
Recent developments in FD involve new insights 
into its pathophysiology with the description of a 
gene mutation and biological pathways involved. 
It is now regarded as a genetic, non-inheritable 
disease caused by missense mutations occurring 
post zygotically in the gene coding for the alpha 
subunit of the stimulatory G protein Gs, in the 
GNAS complex locus in chromosome 20q13 
(gsp mutation). The resulting proteins display 
reduced GTPase activity, with increased adenylyl 
cyclase activation. The mutated cells constitutively 
generate high levels of cAMP and have a high 
proliferation rate. Activation of the Gs alpha/PKA/
CREB pathway induces c-fos overexpression in 
mesenchymal precursor cells, which interferes with 
normal osteoblast differentiation. It has also been 
suggested that increased cAMP may down regulate 
the osteoblastic transcription factor Runx two, 
contributing to abnormal osteoblastic differentiation. 
This is the basis for the histologic hallmark of 
extensive proliferation of fibrous tissue produced by 
the abnormally differentiated preosteoblastic cells. 
Another downstream effect of increased cAMP is 
increased levels of interleukin six, which in turn 
may be responsible for osteoclast recruitment and 
activation and consequently bone resorption. It is 
now possible to test for the genetic mutation in 
peripheral blood samples by genetic amplification 
techniques such as PCR, which may confirm the 
Figure 3. Fibrous dysplasia composed of irregular woven bone 
trabeculae with interspersed fibrous stroma
diagnosis in difficult cases. FGF-23 can be elevated 
in patients with FD, leading to renal phosphate 
wasting and hypophosphatemia. The presence of 
structural alterations involving chromosomes 3, 8, 
10, 12, and 15 suggests that FD may be a neoplastic 
condition with a predisposition to somatic mutations 
of bone-forming mesenchymal tissue.
Curettage with bone grafting is the traditional 
treatment for FD. However, there have been changes 
over the past decades with the introduction of 
medical management with bisphosphonates (mainly 
pamidronate), which are potent inhibitors of bone 
resorption and have a lasting effect on bone turnover. 
Radiographic improvement of the lesions, decrease 
in bone pain, and biochemical markers of bone 
remodeling have been observed with this treatment.
Surgery is indicated for correction of deformities and 
prevention of impending fractures.
Osteochondroma
Osteochondroma is a relatively common benign bone 
tumour. It is more common in males in the first and 
second decades of life and occurs in bones formed by 
endochondral ossification. The metaphyses of long 
bones are the preferred site (distal femur, proximal 
tibia, and proximal humerus) but it may arise in flat 
bones like the ilium and scapula. Most lesions are 
solitary but approximately 15 percent of patients 
have multiple lesions. Multiple osteochondromatosis 
or hereditary multiple osteochondromas (HMO) is 
an autosomal dominant inherited condition where 
multiple osteochondromas develop in several bones, 
leading to significant deformity. 
Histologically, the cap resembles an epiphyseal plate, 
particularly at its base. All osteochondromas usually 
stop growing when the parent growth plates close.
The most significant recent advances are related 
to the identification of the gene mutations 
that characterize HMO and their link to its 
pathophysiology. Mutations of the EXT1 (8q24.1), 
EXT2 (11p11-12), and the recently described EXT3 
(19p) tumor suppressor genes are associated with this 
condition. Loss of genetic material from the long arm 
of chromosome eight is the distinctive cytogenetic 
alteration of osteochondroma. It is hypothesized that 
EXT mutations affect the signaling pathways of the 
growth plate chondrocytes. Indian hedgehog (IHH) 
and parathyroid hormone-like hormone (PTHLH) 
function in a negative feedback loop to inhibit the 
differentiation of proliferating chondrocytes in the 
growth plate. Prehypertrophic chondrocytes express 
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IHH, which stimulates perichondrial cells to produce 
PTHLH. PTHLH in turn inhibits both growth plate 
chondrocyte differentiation and the expression of 
IHH. PTHLH binds to proliferating chondrocytes, 
inhibiting differentiation and apoptosis through 
induction of Bcl-2 production.EXT1 and EXT2 
are transmembrane glycoproteins involved in the 
synthesis of heparin sulfate proteoglycans (HSPGs). 
HSPGs bind to IHH ligands in the extracellular 
environment, which controls their diffusion. 
Mutations involving EXT genes lead to abnormal 
processing of HSPGs and their accumulation in 
the cytoplasm of chondrocytes. Defective HSPG 
production associated with EXT mutations causes a 
disruption in this signaling pathway, which in turn 
causes aberrant maturation and bone growth within 
the proliferating cartilage. 
Treatment is reserved for symptomatic cases. 
Complete excision of the osteochondroma including 
the perichondrium is usually curative. 
Malignant transformation to chondrosarcoma 
has been reported in 1 percent of solitary 
osteochondromas and 1 percent – 3 percent of 
multiple osteochondromas. Most cases are low-grade 
chondrosarcomas.
Enchondroma
Enchondroma is a benign intramedullary mass of 
hyaline cartilage. About 41 percent of the cases 
occur in the small bones of the hands and feet. It may 
also arise in long tubular bones (proximal humerus, 
proximal and distal femur), the ribs, and the spine. 
The metaphysis is a preferred location and the 
lesion is usually asymptomatic. Radiographically, 
enchondroma is well demarcated and radiolucent 
with stippled calcification. Expansion and thinning 
of the surrounding cortex with endosteal scalloping 
may be seen in the small bones. 
Histologically, enchondroma is composed of lobules 
of hypocellular hyaline cartilage without mitotic 
activity or nuclear pleomorphism (Figure 4). It
lacks evidence of permeation of marrow spaces 
or entrapment of preexisting bony trabeculae. 
The differential diagnosis between enchondroma 
and low-grade chondrosarcoma is challenging 
and requires careful clinical, radiological, and 
histopathological correlation. The treatment of 
enchondroma is curettage and bone grafting. Local 
recurrence is uncommon. Most enchondromas 
have a normal karyotype. Structural abnormalities 
of chromosomes 6 and 12 have been described. 
In enchondromas, PTHLH signaling is active, 
but independent of Indian hedgehog (IHH), 
irrespective of the presence or absence of absence 
of enchondromatosis. Heterozygous somatic 
mutations have been detected in at least 50 percent 
of solitary enchondromas and approximately 
90 percent of enchondromas from patients with 
enchondromatosis.
Chondroblastoma
Chondroblastoma is a benign bone neoplasm with 
predilection for the epiphyses of the long bones in 
skeletally immature individuals. Most cases occur 
during the second decade of life. The proximal and 
distal femur, proximal tibia, and proximal humerus 
are most commonly affected. Radiographically, 
eccentric, well-circumscribed, lytic lesion centered 
in the epiphysis with partially sclerotic margins 
is seen. Histologically, chondroblastomas are 
composed of round to polygonal cells with well-
defined cytoplasmic borders. The cytoplasm is 
clear to slightly eosinophilic and ovoid nuclei 
with longitudinal grooves. Randomly distributed 
osteoclast-type giant cells are invariably present. 
Linear pericellular calcification (“chicken-wire”) is 
characteristic (Figure 5).
Figure 4. Enchonroma composed of lobules of hyaline cartilage encased 
by thin rim of reactive bone.
Figure 5. Chondroblastoma composed of sheets of polygonal cells with 
focal chicken wire calcification.
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Chondroblastomas generally express S-100 protein, 
CK8, CK18, and CK19.
Strong expression of the cartilage lineage regulator 
Sox9 has been recently demonstrated.
Structural abnormalities of chromosomes 5 and 8 
seem to occur frequently in chondroblastoma.
Chondromyxoid Fibroma
Chondromyxoid fibroma (CMF) is one of the least 
common bone tumours. The metadiaphysis of the 
proximal tibia and the ilium are commonly affected 
sites. Radiographically, it appears as an eccentric, 
sharply marginated lytic lesion with scalloped 
margins and a sclerotic bony rim. Histologically, 
the tumor is composed of lobules with loose 
myxoid stroma containing spindle- to stellate-shape 
cells. The lobules are separated by fibrous septa 
containing multinucleated osteoclast- type giant 
cells (Figure 6). CMF has a high expression of 
certain cell cycle progression molecules and cell-
to-cell adhesion molecules such as p16, cyclin D1, 
and ALCAM (CD166). These can be assessed by 
immunohistochemistry and have been suggested as 
an aid in distinguishing CMF from chondrosarcoma.
CMF demonstrates strong expression of the cartilage 
lineage regulator S0x9. Chromosome 6 aberrations 
is frequent but heterogenous; regions commonly 
involved include 6p23-25, 6q12- 15, and 6q23-27. 
It has been suggested that these may be helpful in 
distinguishing CMF from chondrosarcoma where 
rearrangements involving these sites of breakpoint 
clustering on chromosome six are uncommon. The 
treatment for CMF is curettage and bone grafting. 
Recurrence occurs in about 25 percent of cases.
Giant Cell Tumour of Bone
GCT is a benign, locally aggressive neoplasm of 
skeletally mature individuals (peak incidence is 
between ages 20 and 45 years), commonly arises 
in the epiphysis of long bones, most commonly 
the distal femur, proximal tibia, distal radius, 
and proximal humerus. Radiographically, GCT 
appears as an epiphyseal, eccentric, and expansile 
lytic lesion without significant marginal bony 
sclerosis, extending into the adjacent metaphysis. 
Histologically, the tumour is composed of 
uniformly distributed osteoclast-type giant cells in 
a background of mononuclear, round, polygonal, 
and spindle cells lacking cytologic atypia (Figure 7). 
Mitoses are variably seen in the mononuclear cells 
and atypical forms are absent. The mononuclear 
cells constitute the neoplastic cell population, 
whereas the multinucleated giant cells are reactive. 
Vascular invasion may be identified in GCT and this 
finding does not correlate with the rate of pulmonary 
metastases. The tumor frequently invades and 
destroys the subchondral bone plate supporting the 
articular cartilage. The behavior of a GCT cannot be 
predicted from its histopathological features. Local 
recurrence occurs in about 20 percent of cases after 
curettage. Lung metastases may occur in two percent 
of cases and most are clinically indolent. Malignant 
transformation may occur at the site of a previously 
excised GCT or following irradiation. 
Recent studies suggest that the neoplastic mononuclear 
cells of GCT are derived from primitive pluripotential 
mesenchymal stem cells and exhibit a preosteoblastic 
phenotype. They express collagen type I, alkaline 
phosphatase, osteocalcin, matrix metalloproteinases, 
macrophage colony-stimulating factor, osteoprotegerin, 
and receptor activator for nuclear factor kappa B 
ligand (RANK-L). The latter is a cytokine belonging 
to the tumor necrosis factor family (TNF-alpha) 
that is a potent stimulator of osteoclast formation, 
differentiation, and maturation. The osteoclast-like 
giant cells express RANK receptor and are most 
Figure 6. Chondromyxoid fibroma exhibting a lobulated architecture 
composed of spindle cells with peripheral osteoclast type giant cells.
Figure 7. Giant cell tumor composed of evenly dispersed osteoclast type 
giant cells among mononuclear cells.
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likely derived from recruited monocytes under the 
provision of the neoplastic mononuclear cells. RANK-L 
expression by the neoplastic mononuclear cells of 
GCT is responsible for giant cell formation and bone 
resorption. Matrix metalloproteinases (MMP-2 and 
MMP-9) are also produced by the mononuclear stromal 
cells and may play a role in osteolysis. GCT has been 
reported to exhibit strong expression of TP73L gene and 
p63 protein in 69 percent – 100 percent of cases.P63 has 
been proposed as a useful marker for the diagnosis of 
GCT. The characteristic chromosomal aberrations seen 
in GCT are telomeric associations. Their significance 
is also unclear. Recurrent numeric or unbalanced 
structural abnormalities are uncommon.
Treatment of GCT is surgery and curettage with 
bone grafting or cementation are most commonly 
used. Bisphosphonates have been used as adjuvant 
treatment for problematic primary, recurrent, and 
metastatic GCT. Bisphosphonates aid in controlling 
the osteolysis associated with tumour growth by 
reducing osteoclast numbers and inhibiting osteoclastic 
resorption. Recent advances in the understanding 
of molecular cell signaling in bone remodeling and 
osteoclast differentiation and activation have led to 
new therapeutic targets, mainly anti RANK-L therapy. 
Denosumab is a human monoclonal antibody against 
RANK-L that inhibits osteoclast-mediated bone 
destruction. Clinical trials are underway with promising 
results as an adjuvant treatment to surgery or as sole 
treatment in inoperable cases, particularly those with 
pulmonary metastases.
Conclusions
The most important advances at the molecular 
and cytogenetic level have shed some light on 
the pathogenesis of certain tumours such as Gs 
alpha mutation in fibrous dysplasia and EXT gene 
mutations in osteochondroma. Clonal aberrations 
found in these tumours have been proposed as 
evidence suggestive of a neoplastic nature. In other 
instances, mutational analysis demonstrates specific 
gene rearrangements that may be useful in the 
differential diagnosis of lesions with clinical and 
pathologic similarities such as fibrous dysplasia 
and low-grade osteosarcoma, chondromyxoid 
fibroma, and chondrosarcoma or GCT and 
aneurysmal bone cyst. One of the most significant 
recent advances is the identification of the RANK/
RANK-L system of cell signaling, which is the 
main regulatory mechanism of osteoclast formation, 
activation, and survival. Its role in normal bone 
remodeling, metabolic bone disease and tumour 
osteolysis has unveiled an important therapeutic 
target for the treatment of such conditions with 
antibodies directed to RANK-L. It has also helped 
us partially understand the molecular and cellular 
biology of GCT of bone. RFA and bisphosphonates 
are therapeutic modalities that are gaining great 
popularity and widespread use by reducing the 
invasiveness and morbidity associated with traditional 
surgical management and providing treatment 
alternatives to inoperable or advanced stage tumours.
Rheumatoid Arthritis: Anti CCP Antibodies 
and Rheumatoid Factor 
Dr Hafsa Majid
Chemical Pathology
Rheumatoid Arthritis (RA) is the commonest 
inflammatory joint disease, affecting nearly one 
percent of the adult population worldwide and 
0.9-1.98 percent of Pakistani population. Although 
the precise etiology of RA remains unknown, there 
is strong evidence for autoimmunity since several 
autoantibodies are associated with the disease. 
It is characterized by multiple deformities and is 
associated with considerable morbidity and mortality. 
Patients with RA follow a variable disease course 
with regard to outcome measures; functional status 
or radiological assessment of joint damage. Early 
identification of patients with RA and, in particular, 
those likely to assume a more rapidly destructive 
form of disease, is important because of the possible 
benefit from early, aggressive intervention with 
disease modifying agents. However there is no single 
clinical, radiologic, or serologic test that enables a 
diagnosis of RA to be made with certainty. As with 
other autoimmune diseases, the diagnosis depends 
upon the aggregation of characteristic symptoms, 
signs, laboratory data, and radiologic findings. The 
main clinically useful biologic markers in patients 
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Table 1: Rheumatoid and non-Rheumatic Diseases Associated with raised RF.
with RA include rheumatoid factor (RF), anti-cyclic 
citrullinated peptide (anti-CCP) antibodies, erythrocyte 
sedimentation rate (ESR), and C-reactive protein (CRP).
1. Rheumatoid Factor
Rheumatoid factor is the autoantibody directed against 
the Fc portion of Immunoglobulin G  (IgG). The RF 
is a well-established diagnostic and prognostic test 
in Rheumatoid Arthritis. High titer RF is relatively 
specific for the diagnosis of RA in the context of a 
chronic polyarthritis, and often appear many years 
before the onset of clinical RA. It was for decades the 
sole serologic criterion widely used as the diagnostic 
and prognostic markers of RA. 
The RF is considered an early marker since its 
presence is linked with an increased risk of developing 
RA in people with mild arthritic symptoms. 
Rheumatoid factor may have some prognostic value 
with regard to disease manifestations and activity, 
and the severity of joint erosions. A seropositive 
RA (ie, RA associated with a positive rheumatoid 
factor test) is often associated with more aggressive 
joint disease, and is more commonly complicated by 
extra-articular manifestations than seronegative RA. 
RF also occurs in other diseases, including a variety 
of rheumatic disorders, many of which share similar 
features, such as symmetric polyarthritis and Non-
rheumatic disorders characterized by chronic antigenic 
stimulation, shown in Table 1. Rheumatoid factors 
have been found in up to four percent of young, 
healthy individuals, higher incidence in elderly.
2. Anti-CCP Antibodies
The aAti-CCP testing is a clinically useful tool 
in diagnosis or exclusion of RA in patients with 
polyarthritis. Patients with an established diagnosis 
of RA who have a positive test for RF, anti-CCP 
antibodies, or both are at a higher risk of developing 
erosive joint damage and functional impairment. As 
a result, such patients should receive anti-rheumatic 
therapy that suppresses disease activity early in the 
course of their disease. The anti-CCP testing offers 
certain advantages including:
l The sensitivity of anti-CCP antibodies is similar 
 to that of RF, but specificity is high (90 to 96 
 percent).
l Anti-CCP antibodies predict erosive disease 
 more effectively in RA patients than RF.  
l It may also be valuable in identifying those 
 patients with early RA who are at increased risk 
 of progressive joint damage. 
l Anti-CCP testing is a clinically useful tool 
 in diagnosis or exclusion of RA in patients 
 with polyarthritis. Anti-CCP may be useful in the 
 differential diagnosis of early stage RA, 
 particularly in the ability to distinguish RA from 
 primary Sjögren’s syndrome or SLE. 
l Among patients with early oligo- or polyarthritis, 
 anti-CCP testing appears to be of predictive 
 value in the RF negative subgroup. 
l In contrast to RF, anti-CCP antibodies are rarely 
 present in the serum of patients with HCV 
 infections.
3. Combination of RF and Anti-CCP Antibodies
 
Testing for both anti-CCP antibodies and RF may be 
better for excluding the diagnosis of RA than testing for 
either antibody alone. Those with early arthritis who are 
RF or anti-CCP antibody positive are at an increased 
risk of developing RA and erosive joint disease, while 
those with neither of these markers are less likely to
develop joint damage. Thus, earlier intervention with 
disease modifying antirheumatic drug therapy may 
be warranted in those with positive markers, while 
symptomatic treatment may be appropriate for those 
lacking both RF and anti-CCP antibodies. Diagnoses 
other than RA should be considered in patients who 
are both RF and anti-CCP antibody negative. Unless 
it is demonstrated that there is an intervention that 
effectively and safely reduces the risk of developing 
RA, there is no role for screening asymptomatic 
individuals for either RF or anti-CCP antibodies. 
Non-Rheumatic DiseasesRheumatic Diseases
Indolent or chronic infection e.g., Hepatitis B virus infectionRheumatoid arthritis — 26 to 90 % 
Inflammatory or fibrosing pulmonary disorders, such as sarcoidosis.Sjögren’s syndrome — 75 to 95 % 
Hepatitis C especially when accompanied by cryoglobulinemia, - 
54 to 76% of cases
Mixed connective tissue disease — 50 to 60% 
MalignancyMixed cryoglobulinemia — 40-100%
Primary biliary cirrhosisSystemic lupus erythematosus — 15-35% 
-Polymyositis/dermatomyositis — 5-10%
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Clinical Utility of Urinary Calcium 
Dr Sibtain Ahmed
Chemical Pathology
Calcium (Ca) is a fundamental element necessary 
to form electrical gradients across membranes, an 
essential cofactor for many enzymes, and the main 
constituent in bone. Under normal physiologic 
conditions, the concentration of calcium in serum 
and in cells is tightly controlled. Calcium exists in 
three states in the body; bound to protein, bound 
to small anions, and in the free (ionized) state. The 
concentration of serum calcium in the ionized state 
is regulated by parathyroid hormone (PTH) and 1, 25 
dihydroxy vitamin D.
Excretion of Calcium
Circulating calcium is excreted by glomerular 
filtration and reabsorbed in the proximal tubules. 
Calcium reabsorption in the proximal tubule 
is affected by tubular sodium concentration, 
whereas PTH induces calcium uptake in the distal 
tubule and the collecting duct. Excess calcium is 
excreted in the urine and the feces. Urine calcium 
levels also reflect dietary intake. In average adult 
urine sample collected over 24 hours, 100–300 
mg of calcium excretion is considered normal. It 
is also important to note that calcium excretion is 
heavily influenced by sodium excretion. Low-
sodium diets tend to decrease calcium excretion 
and vice versa.
Laboratory Indices for Evaluation of Calcium 
Excretion
Although a 24-hour collection is best, random 
urine calcium measurement can also be performed 
to calculate calcium/creatinine ratio or fractional 
excretion of calcium (FECa) on urine specimens.
l 24 hour Ca excretion: The reference range for 
 urine calcium is 100-300 mg/24-hour. 
 Hypercalciuria is >350 mg/24-hour specimen.
l Ca: Cr ratio: A normal reference interval for 
 the urine calcium (mg/dL): urine creatinine 
 (mg/dL) ratio is <0.14. Values exceeding 0.20  
 (for men) or 0.57 (for women) are found in   
 patients with hypercalciuria.
l FECa: Simultaneously 3 - 5 cc of serum is also  
 required for analysis of Ca and Cr. 
 The formula for FECa is as follows: (urine Ca ×  
 serum Cr) / (serum Ca × urine Cr) × 100
 In Familial hypocalciuric hypercalcemia (FHH)  
 the FECa results are usually ≤0.01.
 
Clinical Utility of Measuring Ca Excretion
The primary clinical value of urine calcium 
measurement is to aid in the differential diagnoses 
of patients and direct optimal treatment options 
for patients with abnormal serum calcium. Various 
conditions associated with abnormal urinary Calcium 
levels are enumerated in Table 1.
Hypercalciuria Associated with Hypercalcemia
Primary Hyperparathyroidism
Hypervitaminosis D
Sarcoidosis
Bone metastases
Multiple Myeloma
Corticosteroids
Prolonged immobilization
Paget’s disease
Hypercalciuria with Normocalcemia
Increased Calcium intake
Idiopathic Hypercalciuria
Renal tubule acidosis
X-Linked Hypercalciuria (Dent’s Disease)
Hypercalciuria Associated with Hypocalcemia
Calcium-sensing receptor activating mutation
Hypocalciuria 
Hypoparathyroidism
Pseudo-Hypoparathyroidism
Vitamin D Deficiency
Low calcium diet
Familial Hypocalciuric Hypercalcemia
Renal Osteodystrophy
Medications Causing Hypercalcemia
Thiazide Diuretics
Oral Contraceptives
Table 1: Conditions associated with abnormal Urinary Calcium levels
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HLA (Human leukocyte antigen) B-27 is class 
I surface antigen which is encoded by genes 
present on short arm of chromosome 6  (Fig. 
1A). The HLA genes are the human versions of 
MHC genes that are found in most vertebrates. 
The proteins encoded by certain genes are also 
known as antigens, as a result of their historic 
discovery as a factor in organ transplantation. 
The major HLA antigens are essential elements 
for immune function. Different classes have 
different functions. 
The role of HLA B-27 molecules is presentation 
of peptides to T-cells. The immune system uses  
HLAs to distinguish the body its own proteins 
‘self’ from the proteins made by foreign invaders 
such as viruses and bacteria ‘non-self’. HLA 
B-27 is strongly associated with the condition 
ankylosing spondylitis, which is named due to 
the terms ‘Ankylosing’ or fusing together and 
‘spondylitis’ or inflammation of bones of spine. 
This and other associated inflammatory diseases 
are collectively referred to as ‘spondyloarthritis’. 
It is uncertain how HLA B-27 causes increase risk 
of ankylosing spondylitis. 
Researchers speculates that HLA B-27 may 
abnormally display to immune system peptides that 
trigger arthritis other researchers suggests that joint 
inflammation characteristic of this disorder may 
result from improper folding of HLA B-27 protein 
or the presence of abnormal forms of the protein on 
the cell surface.
Ankylosing spondylitis is two to three times more 
common in males than in females, and it affects all 
age groups including children. The most common 
age of onset of symptoms is the second and third 
decade of life. The effect of the disease is depicted 
in Fig. 1B Symptoms of ankylosing spondylitis 
include back pain and stiffness (worst at night and 
in morning), weight loss, feeling unwell, tiredness, 
pain and swelling of hips, knee or joints, plantar 
fasciitis (pain under heel of foot), aching in chest, 
around ribs. It may be associated with psoriatic, 
colitic and reactive arthiritis. The complications of 
the disease are uveitis (inflammation of eye) and 
issues related to heart and lungs.
HLA B-27 at a Glance
Sheeba Parveen 
Molecular Pathology
Fig.1.B. Diagrammatic Representation of the effect of Ankylosing 
Spondylitis on the Spine.
Fig.1.A. The Organization of HLA Genes on Chromosome 6
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Fig. 2. Detection of the HLA B-27 all  ele. The picture depicts the pres-
ence of DNA on an agarose gel stained with ethi dium bromide. Fluores-
cent bands indicate the presence of DNA in each lane
For molecular diagnosis of ankylosing spondylitis 
a venous blood sample is required for the test. 
DNA is extracted from blood using the sodium 
dodecyl sulphate (SDS)-proteinase K lyses 
method and then amplified by conventional 
polymerase chain reaction (PCR). Using Sequence 
specific primer (HLA-A and HLA–B) primers. 
In addition, PCR for the growth hormones (GH 
1 and GH 2) genes is used as an internal control. 
Amplified product is than analysed by agarose gel 
electrophoresis (Fig. 2).
A positive band of 144 kb obtained in the PCR 
reaction indicates the presence of the HLA-B27 
allele, and based on this the result of the test is 
reported as a ‘presence’ or an ‘absence’ of the 
HLA B27 allele. An internal control is included 
in each PCR reaction to monitor the presence of 
PCR inhibitors in the specimen.
Introduction
1, 25 dihydroxyvitamin D (1,25 (OH) 2D) is the 
most potent and active vitamin D metabolite. It is 
produced in kidney by enzymatic hydroxylation 
of 25-hydroxyvitamin D (25(OH) D). Plasma 
1,25-dihydroxyvitamin D (1,25(OH)2 D) is tightly 
controlled by plasma parathyroid hormone (PTH), 
serum calcium, serum phosphate, and fibroblast-like 
growth factor 23 (FGF-23)
1, 25(OH)2D alone provides essentially no 
information about the nutritional status of vitamin 
D. Consequently, 25OHD is the preferred initial test 
for assessing vitamin D status. Compared to 25(OH)
D, 1,25(OH)2 D circulates in the human body at a 
very low concentration, making its serum levels 
challenging to assess. 1,25 (OH) 2D is a steroid 
like hormone. In target cells, such as classic steroid 
hormones, it binds to a specific cytoplasmic vitamin 
D receptor (VDR); the vitamin D bound to VDR 
then translocates to the nucleus, where its effects 
are initiated at a transcriptional level. The main 
established actions of 1,25(OH)2 D collectively 
increase calcium in the body and modulate the 
skeleton. It increases the intestinal absorption of 
calcium and phosphate, decreases renal excretion of 
calcium and phosphate, suppresses PTH production, 
and regulates osteoblast function and bone resorption. 
Clinical utility of1, 25 (OH) 2D Testing
Measuring serum levels of 1,25(OH)2 D should be 
considered upon suspicion of deficiency or excess of 
1,25(OH)2 D (Table 1). 
It is a preferred test for individuals with 
hypercalcemia or renal failure in addition to 25(OH) 
D testing.  In patients with hypercalcemia, both 
25(OH) D and 1, 25(OH)2D levels are done to rule 
out vitamin D intoxication with disorders that can 
increase 1,25(OH)2 D synthesis, such as lymphoma, 
sarcoidosis, and other granulomatous diseases.
It may also be used as a second-order test in the 
assessment of vitamin D status, especially in 
patients with renal disease and in investigation 
of vitamin D deficiency when suspecting vitamin 
D-dependent rickets due to hereditary deficiency 
of renal 1-alpha hydroxylase or end-organ 
resistance to 1,25 (OH)2D.
Clinical Utility of Serum 1,25OHD Testing
Dr Shabnam Khawaja
Chemical Pathology
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1,25(OH)2 D may be helpful in diagnosing parathyroid 
function disorders. A high serum level of 1,25(OH)2 D, for 
example, may suggest of primary hyperparathyroidism, 
whereas a normal or low serum level is more likely 
found in secondary hyperparathyroidism.
Serial 1,25(OH)2 D levels can be used in monitoring 
the efficacy of treatment in patients receiving 
1,25(OH)2 D supplementation.
NOTE:
The Section of Chemical Pathology, Department of 
Pathology and Laboratory Medicine has initiated the 
testing of 1,25 (OH)2D. The reference interval of1,25 
(OH)2D used in our laboratory is 19.9-79.3 pg/mL.
Answer to LABRAD Quiz
Decreased 1, 25-Dihydroxyvitamin D Levels
Chronic kidney disease
Tumor-induced osteomalacia,
Use of HIV protease inhibitors
Severe 25OHD deficiency
Vitamin D–dependent rickets type 1 (inactivating mutation in the 
1-hydroxylase gene)
Autosomal-dominant hypophosphatemic rickets (mutation of the 
gene coding for FGF-23, which prevents its breakdown)
X-linked hypophosphatemic rickets (mutations that elevate levels 
of FGF-23)
Hypoparathyroidism
Increased 1,25-Dihydroxyvitamin D Levels
Lymphoproliferative disorders
Sarcoidosis,
Tuberculosis
Inflammatory bowel disease
Hereditary vitamin D-resistant rickets (mutations of vitamin D 
receptor coding genes)
Primary hyperparathyroidism
Table 1: Conditions causing high or low 1, 25-Dihydroxyvitamin D Levels
1.1: Hypoparathyroidism is the most common 
 cause of hypocalcemia, which is causing 
 symptoms in this patient. Her presentation 
 soon after birth suggests presence of 
 congenital hypoparathyroidism.
1.2: Serum magnesium levels: Magnesium is 
 required for optimal activity of parathyroid 
 gland. Levels are usually low in 
 hypoparathyroidism.
1.3: The goal of treatment is to normalise the 
 levels of calcium, magnesium and 
 phosphorus. A treatment regimen typically
 includes replacing calcium by giving 
 oral calcium carbonate or gluconate along 
 with 1 alpha vitamin D.
2.1: Symptoms of bone pain and weakness 
 can mean that patient have a coexistent 
 vitamin D deficiency along with senile 
 osteoporosis. For many people, the symptoms 
 are subtle. Yet even without bone symptoms,
 inadequate vitamin D levels can pose other
 health risks
2.2: Biochemical tests to measure calcium, 
 phosphorus, magnesium, vitamin D and 
 parathyroid hormone and bone turnover 
 markers can be performed. Depending 
 upon the symptomatology, tests to screen for 
 secondary osteoporosis can also be considered.
2.3: Bone tumor markers (BTM) are helpful 
 in monitoring bisphosphonate therapy. 
 Early changes in BTM measure the clinical
 efficacy of an anti-resorptive treatment 
 and to reinforce patient compliance. At
 AKUH Clinical Laboratory, N-telopeptide of 
 Type I collagen is performed.
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Clinical and radiological information required 
for the pathological diagnosis of bone tumours. 
Histopathological assessment of a bone tumour needs 
to take into account the clinical background and 
features of the lesion, its radiological appearances 
and the results of relevant laboratory investigations. 
Diagnostic evaluation and treatment should optimally 
be carried out at a centre which specialises in the 
diagnosis and treatment of bone tumours. 
Relevant clinical information should be provided on the 
pathology request form and its content should be 
recorded in the final pathology report. The age of the 
patient is crucial for bone tumour diagnosis as a number 
of bone tumours, both benign and malignant, tend to 
develop most commonly within a given age range (Table 1). 
Some tumours and tumour-like lesions have a 
predilection to arise in certain bones,e.g simple bone 
cyst occurs most often in the proximal humerus of 
a child or adolescent (Table 2). Most bone tumours 
present with bone pain and swelling. Bone pain 
is dull, aching and characteristically worse at 
night characteristically seen in osteoid osteoma. 
Rapid growth is characteristic of some malignant 
tumours but is also seen in some benign tumours 
and tumour-like lesions, such as aneurysmal bone 
cyst, eosinophilic granuloma and osteomyelitis. 
A history of trauma may be notable in cases 
where a post-traumatic lesion (eg haematoma) is 
a possible diagnosis. Local and systemic signs 
of infection need to be distinguished from those 
associated with the growth of a bone tumour, such 
as Ewing sarcoma. Information regarding a pre-
existing skeletal condition should be provided, 
including developmental conditions where there 
are multiple skeletal lesions (e.g fibrous dysplasia, 
osteochondromatosis). It is also important to receive 
information on any relevant extraskeletal disease (e.g 
history of carcinoma) elsewhere in the body. 
The results of laboratory investigations which 
may help in evaluating a bone lesion should be 
communicated to the reporting pathologist. Details 
of the white blood cell count and erythrocyte 
sedimentation rate should be noted if there is 
a possibility that the lesion is a bone infection, 
eosinophilic granuloma, leukaemia or other 
haematological malignancy. Ewing sarcoma and 
‘toxic’ osteoclasts may present with clinical and 
laboratory features 
that resemble 
osteomyelitis. 
If myeloma is 
suspected, protein 
electrophoresis for 
the identification 
of monoclonal 
immunoglobulin 
components in the 
serum or urine should 
be undertaken. 
Laboratory tests 
reflecting bone 
turnover, such as the serum calcium, phosphate 
and alkaline phosphatase should also be known, 
particularly if there is a need to exclude a metabolic 
cause for the development of a bone tumour, such 
as a “brown tumour” of hyperparathyroidism or 
Paget’s disease. The alkaline phosphatase may also 
be elevated in osteosarcoma, ‘blastic’ metastases, 
fracture, polyostotic fibrous dysplasia and other 
conditions. The acid phosphatase may be elevated in 
prostate carcinoma. 
Radiological information is essential for bone 
tumour diagnosis and it is strongly recommended 
that, wherever possible, the pathologist should 
Role of Clinical and Radiological Correlation 
in Orthopaedic Pathology
Dr Nasir Ud Din
Histopathology
Benign
Nonossifying fibroma, simple bone 
cyst,aneurysmal bone cyst, chondroblastoma, 
Langerhans cell histiocytosis, osteoblastoma, 
osteoid osteoma, osteofibrous dysplasia, 
chondromyxoid fibroma, fibrous dysplasia, 
enchonroma
Enchondroma, giant cell tumor, osteoblastoma, 
osteoid osteoma, chondromyxoid fibroma, 
fibrous dysplasia
Fibrous dysplasia, Paget disease
Age (years)
Less than 20
20-40
More than 40
Malignant
Ewing Sarcoma, osteosarcoma 
(conventional, periosteal, telangiectatic), 
Leukemia,neuroblastoma,
Osteosarcoma (parosteal), adamantinoma
Metastatic disease (most common),
Chondrosarcoma,myeloma, Non-hodgkin 
lymphoma, Osteosarcoma (secondary)
Table 1: Peak Age Predilection of Bone Tumors
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personally view the radiological images of a bone 
tumour before issuing a diagnostic report. Where this 
is not possible, it should be recorded in the pathology 
report. 
The precise anatomical location of a lesion in bone 
is important because tumours have a tendency not 
only to develop more commonly in certain bones 
but also more frequently to involve the particular 
anatomical region of an affected bone (Table  3). It 
should also be evident from the radiology whether a 
lesion has originated in bone or extended into it from 
surrounding soft tissues. 
The matrix composition of the lesion may point to 
specific diagnostic possibilities (e.g calcification 
within cartilage tumour or ossification within a 
bone-forming tumour). 
The interface between the 
lesion and surrounding 
bone, particularly 
whether the lesion is 
well or poorly defined, 
should be noted as this 
may favour a particular 
benign or malignant 
diagnosis. A sclerotic 
rim is commonly present 
around slow growing 
lesions and usually points 
to a benign diagnosis. 
A non-sclerotic margin 
is usually found around 
a more rapidly growing 
bone lesion; malignant 
lesions are commonly 
poorly defined and have a 
broad zone of transition.
The pattern of bone destruction should be identified 
as it indicates the rate of growth of a bone lesion. 
A geographic pattern of bone destruction is 
characterized by the presence of well-circumscribed 
lytic areas (maximum dimension more than 1 
cm) with a well-defined margin; this reflects 
the slow growth rate of these lesions, which 
are usually benign tumours (e.g non-ossifying 
fibroma) or locally aggressive/low-grade malignant 
tumours (e.g giant cell tumour of bone, low-grade 
chondrosarcoma). A rim of sclerosis between normal 
host bone and the lytic area may or may not be 
present. A moth-eaten pattern of bone destruction 
is characterized by the presence of multiple 
small lytic areas (usually 2-5 mm) separated by 
identifiable bone; this indicates an aggressive pattern 
of growth and is most often seen in malignant 
neoplasms, although it can be seen in some forms 
of osteomyelitis and langerhans cell histiocytosis. 
A permeative pattern of bone destruction is 
characterized by diffuse marrow involvement in 
which there are multiple tiny lytic areas (< 1 mm 
maximum dimension). This is usually accompanied 
by a broad zone of transition and reflects rapid 
growth of a bone lesion. A permeative pattern occurs 
in malignant tumours such as Ewing sarcoma and 
osteosarcoma, but can also be seen in some benign 
entities such as osteomyelitis and langerhans cell 
histiocytosis.
Radiological evidence of extension of the tumour 
through the bone cortex and involvement of 
Benign
Chondroblastoma, Giant cell 
tumor,Intraosseous ganglion/
geode(associated with arthritis)
Simple bone cyst,Aneurysmal bone cyst, 
Enchondroma, Fibrous dysplasia,Osteomy
elitis,Localized Langerhans cell histiocy-
tosis, chondromyxoid fibroma
Fibrous cortical defect, osteoid osteoma
Juxtacortical chondroma
Fibrous dysplasia, Localized Langerhans 
cell histiocytosis 
Osteofibrous dysplasia 
Location
Epiphyseal
Metaphyseal
Medullary
Cortical
Juxtacortical
Diaphysis
Medullary
Cortical
Malignant
Clear cell chondrosarcoma (very rare 
tumor)
Conventional 
osteosarcoma,chondrosarcoma, 
metastasis, myeloma, lymphoma,
Metastasis (especially lung)
Periosteal osteosarcoma, parosteal osteo-
sarcoma, juxtacortical chondrosarcoma
Ewing sarcoma, lymphoma, myeloma, 
Metastatic disease
Adamantinoma, Metastasis 
(especially lung)
Table 2. Typical Locations of Bone Lesions
Tumor
Adamantinoma
Osteofibrous dysplasia
Parosteal osteosarcoma
Periosteal desmoid
Osteoblastoma
Aneursmal bone cyst
Haemangioma
Chordoma
Epidermal inclusion cyst
Glomus tumour
Simple bone cyst
Location
Anterior cortex of tibia
Anterior cortex of tibia
Posterior cortex of distal femur
Posterior cortex of distal femur
Posterior elements of spine
Posterior elements of spine
Vertebral bodies
Clivus, vertebral bodies, sacrum
Terminal tuft of phalanx 
Terminal tuft of phalanx
Calcaneous
 Table 3: Specific Sites of Selected Tumours
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surrounding soft tissue should be noted as this 
provides evidence of a locally aggressive or 
malignant tumour. The nature of the periosteal 
reaction associated with a bone lesion oftens reflects 
the growth rate of the tumour. When the tumour 
grows slowly, the periosteum forms a thick layer 
of bone. Multiple layers of periosteal new bone are 
formed when there is a succession of fast and slow 
growth phases associated with the enlargement of the 
underlying lesion. The presence of tumour on both 
sides of the cortex (which is not yet destroyed) often 
indicates a very aggressive lesion. 
The presence of multiple lesions within bone 
should be determined as this may suggest 
particular conditions such as multiple cartilage 
tumours (e.g enchondromatosis, multiple 
osteochondromas) or langerhans cell histocytosis, 
brown tumor, fibrous dysplasia, multiple 
myeloma. This feature is also useful in assessing 
whether a malignant tumour is more likely to be 
primary or secondary. With regard to primary 
malignant bone tumours, it may also point to a 
diagnosis of multifocal osteosarcoma or metastatic 
Ewing sarcoma.
Stop at One. Make your first break your last!
CME Seminar on ‘World Osteoporosis Day’
Dr Lena Jafri
Chemical Pathology
The Metabolic Bone Disease Forum of AKU and the 
Department of Pathology & Laboratory Medicine, 
Aga Khan University in collaboration with Pakistan 
Society of Chemical Pathology, Pakistan Orthopedics 
Association and Pakistan Society of Rheumatology, 
organized a CME Seminar on ‘World Osteoporosis 
Day’ on Tuesday, October 20, 2015, at the Medical 
College, Aga Khan University, Karachi Pakistan. 
Renowned experts from Aga Khan University 
delivered talks and complicated cases related to 
osteoporosis were discussed by invited experts. Dr 
Imran Siddiqui, Associate Professor and Interim 
Chair, Department of Pathology & Laboratory 
Medicine who welcomed the participants and 
discussed the importance of such academic activities. 
He appreciated the efforts of Metabolic Bone Disease 
Forum in creating awareness of bone health on 
‘World Osteoporosis Day’. 
 
The links between vitamin D and osteoporosis were 
highlighted by Dr Aysha Habib Khan, Associate 
Professor and Section Head of Chemical Pathology, 
Department of Pathology & Laboratory Medicine. 
She described the work of Metabolic Bone Research 
Group and Metabolic Bone Disease Forum which 
have a strong record of activity over the past years. 
She gave an overview of the burden of osteoporosis 
in Pakistan and shared findings of various studies 
from Aga Khan University Hospital. She shared 
the reality that most hospitals and clinics fail to 
capture the first fracture – leaving patients open 
to a future of suffering and debility. Over 80% of 
fracture patients are never offered screening and/or 
treatment for osteoporosis, despite the fact that there 
are effective medications that can reduce fracture risk 
by as much as 30–70 %. She also emphasized on the 
importance of screening with appropriate laboratory 
investigation in the assessment of metabolic bone 
diseases. 
Dr Maseeh uz Zaman, Associate Professor and 
Section Head Nuclear Medicine, Department 
of Radiology gave a comprehensive talk on 
interpretation and limitations of Dual Energy X-ray 
Absorptiometry (DXA) Scan. He discussed the 
sensitivity of DXA reporting with real life cases. He 
further explained how DXA findings can assist in 
managing osteoporosis. Additionally he talked about 
Dr Aysha Habib Khan delivering a talk on Burden of Osteoporosis in Pakistan
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FRAX, the fracture risk assessment tool a free web-
based clinical scale assessing the 10-year fracture 
risk and need for lifestyle advice, DXA scanning or 
preventive treatment. 
Ms. Muzamila Mughal, a Nutritional Expert, who 
highlighted the importance of diet, exercise and 
lifestyle for good musculoskeletal health, including 
its role in maintaining future mobility and quality 
of life. In line with World Osteoporosis theme 2015 
‘Serve up bone strength throughout life’, she stressed 
that adequate dietary intake of calcium and vitamin 
D is essential for good bone health. 
Management of primary osteoporosis was discussed 
by Dr. Masood Umar, Associate Professor and 
Orthopedic Surgeon. The key aspect of his discussion 
was a comprehensive treatment strategy for patients 
with osteoporosis. He identified the pros and cons 
of various pharmacological therapies available for 
osteoporosis.
Dr Lena Jafri Assistant Professor and Member 
Executive Council Pakistan Society of Chemical 
Pathology emphasized on the need to identify 
secondary osteoporosis in clinical set-up. She 
presented an outline of the approach to secondary 
osteoporosis. She gave an insightful talk on clinical 
utility of available biochemical and radiological 
investigations for identifying secondary osteoporosis 
and provided the audience with a diagnostic 
approach. Additionally she emphasized the 
importance of the need for a Pakistani fracture risk 
assessment tool and discussed the impediments 
in creating one, like lack of fracture registries and 
paucity of data on post- fracture mortality rates. 
Dr Mehmood Riaz, Assistant Professor, Department 
of Medicine, gave an enlightening talk on steroid 
induced osteoporosis. He stated that glucocorticoid-
induced osteoporosis is under recognized and 
undertreated in an estimated one million patients 
who receive glucocorticoid therapy for a wide 
variety of medical disorders, emphasizing that 
glucocorticoids are the most common cause 
of secondary osteoporosis and non-traumatic 
osteonecrosis. 
Real life challenging cases of osteoporosis were 
presented by Dr Hafsa Majid, Resident Chemical 
Pathology and panel of experts pitched in with their 
expertise on diagnosis and management. Panel of 
experts comprised of renowned endocrinologist. 
Saeed Maher, rheumatologist Dr. Saleha Ishaq, 
orthopaedic surgeon Dr. Amin Chinoy and Director 
Kiran Hospital Dr. Akhter. Many questions were 
elicited which made for great discussion among all.
The closing remarks were delivered by Dean 
Medical College, Dr Farhat Abbas who appreciated 
the role of faculty in holding a seminar on World 
Osteoporosis Day and in creating awareness of 
an ignored disease affecting a large part of our 
population. The CME seminar was successful 
in bringing together delegates from the different 
disciplines. The osteoporosis seminar exposed 
the risk factors, highlighted the preventive tools, 
diagnostic caveats 
and management 
strategies of 
osteoporosis. The 
attendees were 
remarkably diverse 
and showed high level 
of enthusiasm. The 
goal of providing a 
forum of information 
exchange among all 
the professionals was 
successfully 
achieved. Group picture of presenters and members of Pakistan Society of Chemical Pathology at the CME Seminar on World 
Osteoporosis Day at AKUH, Karachi Pakistan
One of the presenters with the Dean Medical College, Dr Farhat Abbas 
and Acting Chair Dept. of Pathology and Laboratory Medicine, 
Dr Imran Siddiqui
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